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Abstract 
Background 
Chronic Granulomatous Disease (CGD) is a primary immunodeficiency, 
characterised by serious infections and inflammation. It can be managed 
conservatively, with prophylactic antimicrobials, or curatively with 
haematopoietic stem cell transplant (HSCT). In the UK and Ireland there are 
cohorts of children managed both conservatively and curatively. Previous 
research has shown patients with CGD have low intelligence and increased 
emotional difficulties. Chronic diseases are known to result in poor quality of life. 
This study aimed to evaluate: clinical outcome; quality of life; emotional well 
being and cognitive function in children managed conservatively and curatively.   
Methods 
Children were identified from specialists centres and advertising through special 
interest groups. Clinical data were collected from medical records. Children and 
parents completed questionnaires measuring quality of life, emotional and 
behavioural difficulties and self-esteem. Children underwent brief IQ tests. 
Results were compared to published norms for healthy children. Non-HSCT and 
post-HSCT groups were compared. 
Results 
78 children were identified. 59 (80%) living children were recruited. Clinical 
information was available for 62 children (four deceased). 30 (48%) children 
had undergone HSCT. Children with CGD had 0.71 episodes of 
infection/admission/surgery per CGD life year (95%CI 0.69-0.75 events per 
year). Post-HSCT children had 0.15 events per transplant year (95%CI 0.09-
0.21 events per year). Post-HSCT survival was 90%. 
Parents and children reported quality of life significantly below normal for in the 
non-HSCT group.  Post-HSCT scores were not significantly different from 
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healthy norms. Parents of non-HSCT children reported increased emotional 
difficulties compared to healthy children. IQ was normal in both groups. 
Conclusions 
Children with CGD have more serious infections, episodes of surgery and 
admissions compared to post-HSCT children. They also have poorer quality of 
life and are at risk of emotional difficulties. Post-HSCT children have normal 
quality of life. Cognitive function is normal in both non-HSCT and post-HSCT 
children.
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Chapter 1 Introduction 
 Chronic Granulomatous Disease (CGD) is a rare inherited primary 
immunodeficiency, characterised by recurrent bacterial and fungal infections. 
Mutations in the genes encoding subunits of the enzyme nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase result in failure of the oxidative burst 
required by phagocytes to eradicate organisms. CGD is associated with 
abnormal inflammatory responses leading to colitis, chorioretinitis and 
granulomas in such places as the liver, lung, skin and lymphoid tissue. Despite 
management of CGD improving over recent years, patients continue to have 
reduced life expectancy[1]. Outcomes following haematopoietic stem cell 
transplantation (HSCT) have shown great promise in patients with CGD with a 
marked reduction in hospital attendance, compared with pre-transplant 
attendance rates, despite ceasing all antimicrobial prophylaxis[2]. CGD has also 
been treated with gene therapy, albeit with limited success to date[3].  
Chronic diseases are well recognised to impact on quality of life. Now that 
survival rates following HSCT for primary immunodeficiency have improved, 
there is a greater focus on wider measures of health and quality of life post-
HSCT. There have also been concerns about cognitive outcome and 
behavioural difficulties in some children undergoing HSCT for primary 
immunodeficiencies[4].There are few published data on the psychological 
impact of CGD or curative treatment for it. However, one study of patients with 
CGD referred for psychological assessment indentified lower than expected 
cognitive function amongst this selected sample[5]. Emotional difficulties have 
also been demonstrated in children with CGD[6]. 
There continues to be discussion in the international community about which 
patients with CGD should be treated with HSCT. There are no data that show 
whether conservative management or HSCT have an effect in terms of quality 
of life and emotional well being. This thesis describes studies that review clinical 
outcome in children with CGD treated conservatively or curatively, and 
addresses the issues of cognitive function, emotional wellbeing and quality of 
life.
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1.1 History of CGD 
In 1957, Bridges et al published information on four boys with 
hypergammaglobulinaemia, recurrent infections and granulomatous lesions 
which were distinct from other granulomatous conditions[7]. At a similar time, 
Landing and Sharkey also published a description of two males with recurrent 
infections and infiltration of visceral organs with lipid histiocytes containing 
yellow-brown pigment[8]. The condition was described as fatal granulomatous 
disease of childhood as all of the initial cases died in early childhood. Over the 
next few years, however, the use of antibiotics and surgical drainage of 
abscesses improved survival in to the second decade of life[9]. With improved 
survival, the word “fatal” was dropped and it was renamed Chronic 
Granulomatous Disease of Childhood in 1967[10].  
 Nine years after the original descriptions of CGD, the immune defect started to 
be understood in more detail. In 1966 Holmes et al documented the failure of 
phagocytes to destroy ingested Staphylococcus aureus in three affected 
boys[11]. A year later the same group identified the failure of the oxidative burst 
as an important factor in defective intracellular killing by polymorphonuclear 
leukocytes in CGD patients[12]. Hydrogen peroxide production was identified as 
a key component of the process of destroying ingested micro-organisms and its 
role in CGD was highlighted when it was demonstrated that organisms that 
produce their own H2O2 could be destroyed by leukocytes from patients with 
CGD[13].  In 1968 Baehner and Karnovsky proposed two possible enzyme 
defects, either affecting nicotinamide-adenine dinucleotide (NADH) oxidase or 
nicotinamide-adenine dinucleotide phosphate(NADPH) oxidase[14]. In fact, they 
concluded NADH oxidase was more likely to be the primary enzyme involved in 
the oxidative burst. It wasn’t until 1975 that NADPH oxidase was recognised as 
the defective enzyme in CGD[15].  
   
3 
 
1.2 NADPH oxidase 
NADPH oxidase is an enzyme involved in oxidation of NADPH, releasing 
electrons and protons that move across a membrane to combine with oxygen, 
producing superoxide which is rapidly transformed to hydrogen peroxide by 
superoxide dismutase. Superoxide and hydrogen peroxide are known as 
primary reactive oxygen species (ROS). During the 1980s-1990s our 
understanding of the structure and function of NADPH oxidase increased 
dramatically. The first component to be described was a b-type cytochrome  
which was found to be absent in 19 men with CGD[16]. It was found to reside in 
the membrane of specific granules in unstimulated neutrophils but to move to 
the plasma membrane when cells were stimulated[17, 18]. It was proposed to 
form an electron transport chain to generate O2- required to form highly reactive 
oxygen species. In 1987 Segal identified the two components of the b-type 
cytochrome (cytochrome b-558) [19], later known as the gp91phox (also known 
as NOX2[20]) and p22phox subunits. In the same year Umei et al identified the 
component that would come to be known as p67phox[21] and Curnette et al 
demonstrated the importance of the cytosolic factor, later to be known as 
p47phox, for a functional oxidative burst[22]. It was not until 1993 that the final 
major component, p40phox was identified by Wientjes et al[23].  
It is now clear that there are six components to the dormant NADPH oxidase, 
five phox components plus the GTP-binding proteins Rac1/2. The gp91phox 
and p22phox are found in their dormant state in the membrane of specific 
granules within the phagocyte[24]. When activated, the cytochrome b-558 is 
moved to the plasma membrane which forms the phagosome[25](Figure 1). 
p47phox, p67phox and p40phox are found in the phagocyte cytosol. In vitro 
studies have demonstrated that activation of NADPH oxidase begins with a 
change in the phosphorylation of p47phox[26, 27]. This process alters the 
p47phox/p67phox/p40phox complex in the cytosol and results in it translocating 
to the membrane where it is then associated with the cytochrome b-558 complex. 
Once in the membrane p47phox stabilises the interaction between p67phox and 
cytochrome b-558[28] which is required to generate the superoxide[29]. Rac1 
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interacts with p67phox[30] and it has recently been demonstrated that 
preventing binding of Rac1 with p67phox prevents superoxide formation in a 
dose dependent manner[31].  Rac2 has been found to be associated with the 
cytosolic components of NADPH oxidase, migrating to the membrane with 
p47phox and p67phox in healthy cells but not p47phox deficient cells[32].  
Inhibition of Rac2, similar to Rac1, inhibits superoxide production in a 
concentration dependent manner[33]. Rap1A is located in the granule 
membrane in association with cytochrome b-558 and is moved to the plasma 
membrane alongside the other components of NADPH, it appears to play a 
regulatory role and may be involved in deactivation as well as activation of 
NADPH oxidase[25].
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Figure 1:NADPH Oxidase activation, demonstrating the membrane and cytosolic components of 
the NADPH complex. On activation cytosolic components move to the membrane, resulting in 
oxidation of NADPH and release of hydrogen ions which combine with superoxide to produce 
reactive oxygen species. From: Assari T. Chronic Granulomatous Disease; fundamental stages in 
our understanding of CGD[9] 
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Defects in gp91phox, p22phox, p47phox and p67phox are well recognised to 
lead to CGD. Until recently, p40phox deficiency was not considered as a cause 
of a CGD phenotype. In a cell free assay, p40phox is not required for NADPH 
activity[25]. It has been shown that p40phox is a binding partner for p67phox 
and is reduced in cases of p67phox deficient CGD[23]. More recently it has 
been shown that p40phox is important in upregulation of NADPH oxidase 
activity through binding to phosphatidylinositol 3-phosphate (PtdIns(3)P) in 
membranes, so targeting the p67phox to the correct area necessary for 
activation of ROS formation[34]. Mutations in p40phox prevent binding of 
PtdIns(3)P. In p40phox-/-  mice this results in failure of neutrophils to kill 
Staphylococcus aureus as seen in other causes of CGD[35]. In 2009 the first 
case of human p40phox mutation causing granulomatous colitis and impaired 
NADPH oxidase activity was described[36]. 
Rac2 deficiency has been described in humans but this does not lead to a 
typical CGD phenotype. A case report of an infant describes multiple, rapidly 
progressing soft tissue infections with poor wound healing. Defects in neutrophil 
chemotaxis, ingestion, degranulation and ROS formation were demonstrated 
and a point mutation in the Rac2 gene identified[37, 38]. 
1.3 NADPH oxidase and microbial killing 
Opsonisation of a microbe, with complement or antibody, allows recognition by 
surface receptors on the phagocyte which triggers the process of ingestion and 
the production of a phagosome(Figure 2). The phagosome is derived from 
invagination of the cell membrane and various granules (gelatinase, specific 
and azurophil). The resulting phagolysosome, which is responsible for microbial 
killing, has cytochrome b-558 in the membrane. The hydrogen peroxide 
generated by the NADPH oxidase is used to generate hypochlorous acid when 
combined with chloride, catalysed by myeloperoxidase [39, 40].  H2O2 and 
hypochlorous acid have a direct role in attacking ingested micro-organisms, but 
also optimise the local environment for cationic microbicidal proteases. Influx of 
ROS in to vacuoles results in a negative charge within the vacuole, driving a 
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compensatory movement of positively charged potassium ions across the 
membrane in to the vacuole[40]. Proteases, cathepsin G and elastase, are then 
activated through the generation of the potassium rich environment. Recent 
work has suggested that these neutrophil granule proteases play an important 
role in direct microbial killing. Studies in which the influx of potassium into the 
vacuole was blocked, demonstrated complete lack of microbial killing despite 
normal production of ROS[41]. Mice made deficient in the proteases 
succumbed to staphylococcal and candida infections despite having normal 
superoxide production[40].  However, contradictory work showed mice deficient 
in neutrophil elastase and cathepsin G did not succumb to Aspergillus 
fumigatus or Burkholderia cepacia infection, whereas, the CGD model p47phox 
deficient mice did[42]. Given that staphylococcus, Aspergillus and Burkholderia 
are all important pathogens in CGD this perhaps reflects the complexity of 
human defences against infection.
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Figure 2:Extracellular & intracellular ROS formation. NADPH oxidase components gp91 and 
p22phox are present on granule and cellular membranes. Cytosolic components can move to these 
membranes for activation of NADPH oxidase and generation of ROS. From Intracellular generation 
of superoxide by the phagocyte NADPH oxidase: How, where, and what for? Bylund et al[43] 
ecROS = extracellular reactive oxygen species 
phROS = phagosome reactive oxygen species 
nphROS = nonphagosomal intracellular reactive oxygen species 
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Another mechanism used by neutrophils to kill microbes has also recently been 
described, and shown to be defective in patients with CGD[44]. Neutrophil 
extracellular traps (NETs) are formed from cationic antimicrobial peptides and 
proteins mixed with chromatin. These are released from neutrophils to bind and 
kill bacteria[45] and fungi such as candida[46]. NETs kill micro-organisms by 
providing a high local concentration of antimicrobial peptides whilst, at the same 
time, minimising tissue damage by sequestering the granule enzymes. 
Neutrophils from patients with CGD fail to form NETs when activated with 
Staphylococcus aureus or phorbol 12-myristate 13-acetate (PMA). However, 
when stimulated with a hydrogen peroxide forming enzyme they do produce 
NETS similar to neutrophils from healthy people. Further studies have 
demonstrated that NET formation in neutrophils stimulated by PMA requires the 
presence of singlet oxygen. This is formed from hypochlorous acid and 
hydrogen peroxide[47] and does not occur in neutrophils from patients with 
CGD[48]. Bianchi et al demonstrated that NET formation could be restored by 
gene therapy in a patient with CGD, leading to removal of A. nidulans conidia 
and hyphae and cure of clinical pulmonary aspergillus infection[49]. This 
suggests the importance of NADPH oxidase driven ROS production in the 
process of NET formation and gives another mechanism by which people with 
CGD are prone to infection[44]. However, our understanding of NETS is rapidly 
evolving, and there have been contradictory studies which have shown NET 
formation to be NADPH oxidase independent[50]. These differences may reflect 
the different stimuli used and it is likely our understanding of this area will 
change and deepen over the next few years as more is published. 
Recently, NADPH oxidase dependent ROS have also been recognised to be 
important in neutrophil chemotaxis. In a study screening for inhibition to 
neutrophil migration in-vitro, they identified that diphenyleneiodonium chloride (a 
flavoprotein inhibitor known to impair NADPH oxidase activity[51]) significantly 
impaired healthy neutrophil directionality on an EZ-TAXIScan chemotaxis 
device[52]. Further investigation using a mouse model demonstrated reduced 
chemotaxis of abnormal CGD neutrophils compared to wild type neutrophils in 
response to peritoneal inflammation. In-vitro testing of neutrophils from a single 
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patient with X-linked CGD demonstrated  that they had a lack of directionality, 
more frequent formation of multiple pseudopodia, and slow migration toward the 
direction of higher chemoattractant[52]. Further work is required in a larger 
cohort of CGD patients to confirm whether this is a further mechanism causing 
the predisposition to infection seen in CGD.   
Another role for NADPH oxidase may be in cell surface receptor expression. 
Hartl et al showed that neutrophils from CGD patients had reduced expression 
of Toll Like Receptor (TLR)5, TLR9, CD11b, CD18, CD35, and CXCR1 when 
compared to normal controls. Reduced TLR5 expression was associated with 
impaired neutrophil activation by bacterial flagella. Reduced CD11b and CD18 
resulted in impaired phagocytosis of Staphylococcus aureus and reduced 
CXCR1 resulted in impaired chemotaxis. TLR5 and CD18 expression were 
inversely correlated with frequency of lymphadenitis and pneumonia 
respectively. Inhibition of NADPH oxidase in control phagocytes in vitro resulted 
in decreased TLR5 and TLR9 expression along with impaired function of 
TLR5[53].  
1.4 Mechanism for CGD hyperinflammation 
The mechanism of inflammatory complications of CGD remains poorly 
understood, however, our understanding is evolving all the time. Over recent 
years a number of hypotheses have been put forward implicating a number of 
different cells and pathways. Some of these have good evidence for 
involvement in CGD hyperinflammation and others less so. It is likely that the 
process is complex and many factors are involved. Patients with CGD certainly 
exhibit increased levels of proinflammatory cytokines [54, 55], but the reason for 
this and role of ROS remains unclear. 
Inflammasomes, large cytoplasmic complexes that have a role in activating pro-
inflammatory cytokines (interleukin -1β (IL-1β) and interleukin -8(IL-8)) in 
response to microbial products have been implicated in CGD 
hyperinflammation[56]. It was proposed that NADPH oxidase generated ROS 
were important in activation of the inflammasome[57]. However, this has more 
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recently been called in to question by findings from studies which show cells 
from CGD patients can exhibit high levels of caspase-1 and interleukin-1 
despite having inactive NADPH oxidase. Recent work has demonstrated 
increased levels of caspase-1(required to activate IL-1β) and IL-1β itself in CGD 
monocytes although not macrophages. In particular, monocytes from patients 
with CGD colitis had high levels of caspase-1 and IL-1. Treatment of these 
patients with Anakinra (an IL-1 receptor antagonist) only produced minimal 
improvement in symptoms despite significant reduction in IL-1 production [55]. 
Another study has shown that cells from gp22phox deficient CGD patients are 
capable of secreting normal quantities of IL-1β in response to activators for 
stimulation of the inflammasome NLRP3. It is not in doubt that CGD patients 
can have high levels of caspase-1 or interleukin 1β, but it appears that this is 
not due to NADPH oxidase dependent ROS activation of the inflammasome 
[58]. 
Other recent work has demonstrated that NADPH oxidase is important in the 
activation of Nfr2, an anti-inflammatory transcription factor. In a p47phox 
deficient mouse model macrophages were shown not to have increased Nrf2 
after stimulation with zymosan when compared to wild type[59]. 
Indoleamine 2,3-dioxygenase (IDO), a tryptophan catabolising enzyme, which is 
important in regulating immune responses and suppressing inflammation was 
widely believed to require ROS for enzymatic activity. A CGD mouse model 
demonstrated a block in the tryptophan metabolism pathway that resulted in 
defective regulatory T cell activity and acute lung inflammation in mice with 
Aspergillus infection so providing a good explanation for inflammation[60].	  
However, in vitro studies using monocytes, dendritic cells, and 
polymorphonuclear leukocytes from humans with CGD have failed to 
demonstrate reduction in metabolites therefore showing no block in the 
pathway[61, 62]. Recent work on the activation of IDO has helped explain this 
as it has been demonstrated that IDO  is activated in-vitro by cytochrome b5 
rather than superoxide[63].  
   
12 
 
Another possible mechanism put forward is impaired peripheral regulatory T cell 
induction by macrophage derived ROS. Impaired regulatory T cell function has 
been demonstrated in rats and in-vitro studies with macrophages from patients 
with CGD[64]. However, defects in regulatory T cells are more commonly 
associated with the development of autoimmune disease which does not 
appear to be a major component of CGD. 
A theory with good evidence to support it, is that of defective apoptosis. 
Clearance of activated and infected neutrophils occurs when macrophages 
recognise phosphatidylserine (PS), on the neutrophil surface[65] and this 
appears to be NADPH oxidase ROS dependent[66]. Macrophages also require 
functional NADPH oxidase in order to phagocytose the neutrophils and this has 
been shown to be defective in cells from X-linked CGD patients and in normal 
macrophages treated with an NADPH oxidase blocking agent[66]. Macrophages 
have to be “programmed” to clear apoptotic cells and this requires signalling 
through the peroxisome proliferator-activated receptor gamma (PPARγ). Using 
a mouse model of acute peritonitis it was demonstrated that CGD mice had 
decreased PPARγ signalling compared to wild type mice but that this could be 
restored with the administration of pioglitazone, a PPARγ agonist[67]. 
Because neutrophils from CGD patients are more resistant to apoptosis it 
results in accumulation of cells which then degrade and release their 
intracellular constituents, resulting in inflammation[68]. Recognition of apoptotic 
cells is also, in itself, anti-inflammatory as it leads to the release of anti-
inflammatory mediators such as transforming growth factor beta (TGFβ), which 
suppress cytokine and chemokine release[69]. It was recognised back as early 
as 2003 that macrophages from CGD patients produce significantly less anti-
inflammatory factors such as TGFβ[70]. 
1.5 Genetics 
Initially CGD was thought to be purely an X-linked disease as the original cases 
were male. However, in 1968 Quie et al described two females with the same 
findings suggesting a second  autosomal recessive pattern of inheritance[71]. 
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With the advent of the ability to identify and map genes the inheritance of CGD 
has become clearer. The abnormal CYBB gene on the X chromosome (Xp21.1)  
was first cloned in 1986 by Royer-Pokora et al[72]. The gene for p47phox, later 
named NCF1 located on chromosome 7q11.23, was identified and cloned by 
Volpp et al three years later[73] and the NCF2 gene for p67phox on 
chromosome 1q25  was cloned in 1990[74] along with the CYBA gene located 
on chromosome 16q24 encoding for p22phox[75]. The gene for p40phox, NCF4 
located on chromosome 22q13.1 was the last to be identified in 1996[76]. 
Worldwide, the most common form of CGD is due to mutations in CYBB, 
accounting for approximately two thirds of cases[77]. No single mutation is 
responsible for all cases of X-linked CGD, single nucleotide substitutions are 
the most common defect but deletions and insertions are also found[78]. Most 
people with X-linked CGD have no gp91phox expression, however some have 
reduced or normal amounts of non-functional protein[79]. It has been shown 
that patients with nonsense, frameshift, splice or deletion mutations have no 
superoxide production or protein expression but certain missense mutations 
with little effect on protein expression have absent NADPH oxidase function[79]. 
A case of X-linked CGD in a 61 year old man has been described after he 
presented with an unusual skin rash. He was found to have normal gp91phox 
expression on Western blotting, but no superoxide production[80]. Somatic 
mosaicism has also been described in two patients with X-linked CGD, resulting 
in small populations of normal cells[81]. Interestingly, two cases of gp91phox 
deficient CGD patients have been described with no superoxide production 
whilst maintaining some degree of hydrogen peroxide production. These 
patients both had mutations that interfered with the interaction between 
gp91phox and p47phox. It was hypothesised that superoxide generation was 
bypassed by electron accumulation at FAD which then pass directly to oxygen 
to produce hydrogen peroxide[82]. 
Autosomal recessive CGD usually occurs as a result of defects in p47phox, 
p22phox and p67phox. The most common form, caused by mutations in the 
NCF1 gene, is responsible for approximately 20-25% of cases of CGD overall, 
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whilst mutations in CYBA and NCF2 are each responsible for approximately 5-
6% of cases[83-85]. Only one patient has been described with a mutation in 
NCF4[85]. CYBA and NCF2 mutations are heterogeneous, however, a single 
NCF1 mutation is responsible for the majority of cases of p47phox deficient 
CGD (a dinucleotide deletion at the start of exon 2)[85]. The majority of 
autosomal recessive mutations result in absent protein expression. However, a 
few result in diminished, or occasionally normal protein expression[85]. 
Residual NADPH oxidase activity has been demonstrated in brothers with 
p67phox deficient CGD who were diagnosed at the ages of 58 and 53 due to 
their atypical history[86]. 
There are dramatic differences in the number of X-linked and autosomal 
recessive cases according to ethnic background. As can be seen from the 
European registry, the percentage of autosomal recessive cases varies 
between 11-83% according to ethnic background (Table 1). 
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Country/Region of 
origin 
Total CGD Type 
  X-linked (%) Autosomal 
Recessive (%) 
France 84 75 (89) 9 (11) 
Germany 69 54 (78) 15 (22) 
The Netherlands 62 43 (69) 19 (31) 
Arab/North African 38 11 (29) 27 (71) 
Poland 30 21 (70) 9 (30) 
Spain 25 16 (64) 9 (36) 
Sweden 24 12 (50) 12 (50) 
Switzerland 24 19 (79) 5 (21) 
Denmark 22 12 (55) 10 (45) 
Israeli 16 9 (56) 7 (44) 
Turkey 12 4 (33) 8 (67) 
Former Yugoslavia 8 7 (88) 1 (12) 
Belgium 6 5 (83) 1 (17) 
East & South Asia 6 1 (17) 5 (83) 
Italy 2 1 1 
Austria 1 0 1 
Total 429 290 (67) 139 (33) 
Table 1: The cohort of CGD patients divided according to nationality/ethnic background and type of 
CGD from van den Berg JM, et al. [77] 
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It remains controversial as to whether there are any clinical differences 
according to genetic defect. Some epidemiological studies have shown a milder 
clinical course for those with p47phox deficient CGD when compared to X-
linked forms, demonstrating fewer complications and longer life expectancy[77, 
87].  However, this is more likely to be related to residual NADPH oxidase 
activity (and therefore microbial killing) rather than inheritance per se. In a large 
study of 287 patients from 244 kindreds, those with p47phox deficiency and 
gp91phox missense mutations had significantly better survival than other 
mutations in gp91phox[79]. It was demonstrated that these patients had greater 
residual NADPH oxidase activity when compared to those with nonsense, 
frameshift, splice, and deletion mutations in gp91phox. Even small amounts of 
residual ROS production (1% of normal) resulted in improved survival[79].  It is 
likely that the contradictory findings in epidemiological studies reflect the various 
different genetic mutations present in the local CGD population. 
 
1.6 Diagnostic tests 
CGD is diagnosed by demonstrating the failure of phagocytes to produce 
reactive oxygen species. The nitroblue tetrazolium test (NBT) is the most well 
known. With a normal respiratory burst, leukocytes reduce the nitroblue 
tetrazolium dye to insoluble formazan which is a deep blue colour. It is a 
measure of superoxide production which takes place inside phagocytes.  The 
dye cannot leave the cells, making them easily visible through a microscope. 
The inability of leukocytes from children with CGD to reduce nitroblue 
tetrazolium was first identified in 1967[88] and since then it has remained a 
widely used investigation. It was also developed into a quantifiable test by lysing 
the cells in potassium hydroxide and dissolving the formazan allowing 
spectrophotometric measurement[89]. The NBT can be used to detect X-linked 
CGD carriers as they will demonstrate a mixture of normal and abnormal 
neutrophil populations. It must be noted, however, that diagnosis of CGD in 
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patients with residual ROS production may be missed on the NBT as will show 
faint blue staining[90]. 
Other methods to demonstrate NADPH oxidase activity, or lack of it, have 
included measuring oxygen consumption with an oxygen electrode[91], 
ferricytochrome c reduction and chemiluminescence assays[89]. However, 
these are rarely used now due to the introduction of flow cytometry methods 
with dyes sensitive to the production of reactive oxygen species. One of the 
most commonly used agents dihydrohodamine -1,2,3, (DHR) enters cells and is 
oxidised to rhodamine – 1,2,3 after stimulation of the cells with PMA. 
Histograms are produced for unstimulated and stimulated cells (Figure 3) and in 
CGD patients the expected peak of stimulated cells is not present (Figure 4). A 
broad histogram can be seen in patients with autosomal recessive forms of 
CGD and some with variant X-linked CGD. This test can also be used to assess 
for X-linked CGD carrier status (Figure 5). A peak of cells that do not respond 
following stimulation are identifiable. The peaks are quantifiable, giving a 
percentage of functioning respiratory burst. The limitation of this technique is 
that the oxidation reaction is dependent on peroxidise and therefore will be 
abnormal in anyone with myeloperoxidase deficiency. However, this is 
distinguishable from a truly absent response in CGD.
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Figure 4: Histogram for stimulated neutrophils from CGD patient 
 
 
Figure 5: Histogram for female CGD carrier neutrophils 
 
 
Reproduced with permission: Dawn Barge, Clinical Immunology Laboratory, Royal Victoria Infirmary, Newcastle
Figure 1: Histogram of healthy neutrophils, stimulated & unstimulated 
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Once a diagnosis of CGD has been made by demonstrating failure of the 
oxidative burst, it is important to identify which component of NADPH is 
defective. Clinically it is important to know whether the condition is inherited in 
an X-linked or autosomal recessive pattern, to aid counselling of families. In 
many cases it is possible to identify absent NADPH oxidase components using 
Western blotting or flow cytometry[92, 93](Figure 6).  
 
Figure 6: Flow cytometric analysis of neutrophils from patients and from a healthy (positive) 
control with specific antibodies against human NADPH-oxidase components.  Koker et al. [93] 
In those individuals that have a mutation resulting in normal protein expression, 
but absent or severely reduced enzymatic activity, it is possible to narrow the 
search slightly by using a cell free assay, to identify whether the defect is in the 
cytosolic or membrane bound compartment of NADPH oxidase[94]. It must be 
remembered, however, that gp91phox and p22phox are required to stabilise 
each other, so, if one is absent, the other will also be undetectable. In these 
cases it is possible to look for gp91phox expression in the neutrophils of female 
relatives. 
Once the defective NADPH component has been identified mutation analysis 
can is performed.  Gene sequencing for CYBB, CYBA, NCF2 and NCF4 can be 
performed from genomic DNA. Sequencing NCF1 is more difficult because 
there are pseudogenes on either side. However, techniques have been 
developed to perform this analysis[95]. Demonstrating a genetic mutation is 
important for genetic counselling of families. 
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1.6.1 Carrier status 
Random X chromosome inactivation early in fetal development of 
haematopoietic precursor cells in female carriers of CGD results in a mosaic 
pattern of wild type and mutated X chromosomes, producing a mixture of 
gp91phox positive and negative phagocytes. The overall degree of NADPH 
activity will be reduced, but can range from near normal to, in rare cases, 
severely depleted resulting in symptoms of CGD[96, 97]. It must be 
remembered however, that X-linked cases can occur as a result of a new 
mutation in the germ line and, therefore, mothers may not be identified as 
carriers[98]. For autosomal recessive CGD it is only possible to diagnose 
carriers of the mutation through genetic analysis. 
1.6.2 Prenatal diagnosis 
Prenatal diagnosis is possible for CGD in women known to be carriers of the 
disease. For many years it has been possible to measure NADPH oxidase 
activity in fetal neutrophils[99]. However, fetal blood sampling can only be 
performed from approximately 16-18 weeks gestation. More recently, genetic 
diagnosis has become possible from cells in amniotic fluid or chorionic villus 
sampling[100, 101]. This is important as it can allow families known to be at risk 
of having a child with CGD to make decisions about how they wish to progress 
with an affected pregnancy. This has been successfully used in Denmark to 
provide a healthy sibling for a child with CGD and provide umbilical cord blood 
for later HSCT for the affected child[102]. 
1.7 Clinical features 
Because CGD is a rare disease, much of our early understanding of the clinical 
features come from case reports and small case series. However, data from a 
number of larger registries have been published in recent years, giving us a 
broader understanding of the clinical features of CGD at a population level. 
Three European series have been published; one from the UK and Ireland, 
consisting of 94 patients[1], one from Italy including 60 patients[103] and a 
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European group (excluding the UK and Italian data) consisting of 429 
patients[77]. There are also small series from Israel (38 patients)[87] and 
Turkey (26 patients)[104]. The other very large series comes from the American 
registry which was compiled slightly earlier than the UK registry and results of 
which were published in 2000 for 368 patients[105]. 
The most common manifestations of CGD are bacterial and fungal infections, 
usually with catalase producing bacteria and fungi such as Staphylococcus 
aureus, Aspergillus species, enteric gram negative bacteria and Burkholderia 
cepacia[78]. Catalases are enzymes that convert hydrogen peroxide in to water 
and oxygen. Catalase negative organisms are thought to be less important in 
CGD  because hydrogen peroxide is not broken down and can be used by the 
defective neutrophils in place of their own H2O2 production[106]. However, this 
theory has been opened up to debate. Catalase negative Staphylococcus 
aureus and Aspergillus nidulans have been shown to be as virulent as catalase 
positive organisms in mouse models[107, 108]. There have also been case 
series of infections with unexpected catalase negative organism in patients with 
CGD such as Actinomyces and Haemophilus species[109, 110]. Given that our 
understanding of the mechanisms by which NADPH oxidase is involved in 
micro-organism killing has evolved to encompass more than just the direct 
effects of ROS this is perhaps unsurprising. However, the virulence of catalase 
negative organisms in CGD remains yet to be fully explained. 
CGD is usually diagnosed in early childhood, but the diagnosis can be delayed 
in to adulthood in some cases. The median age at diagnosis was 2.7 years in 
the UK [1]. Patients with X-linked disease are normally diagnosed at an earlier 
age than those with autosomal recessive disease. In the European series, 
mean age at diagnosis in X-linked disease was 4.9 years compared to 8.8 years 
for autosomal recessive disease[77]. Females are often older at diagnosis, in 
the UK series the mean age for females was 15.3 years, compared to 2.5 years 
for males[1]. This possibly reflects the fact that CGD is normally thought of as a 
male disease and can be over looked in girls. It may also reflect the less severe 
course seen in some series of autosomal recessive patients. There are 
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occasional reports of much older people being diagnosed with CGD, including 
people in their 60s[111]. The oldest man reported in the literature from America 
was aged 69 years at diagnosis[112]. He had x-linked CGD with non-functional 
protein expression and a small amount of residual NADPH activity. The 
diagnosis was made in him following an episode of Burkholderia cepacia 
sepsis. The family history came to light that his grandson had a presumptive 
diagnosis of CGD (after death from Burkholderia cepacia sepsis) and his 
daughter had been identified as a carrier. 
1.7.1 Infection  
In the UK and Ireland, the most common presentations of CGD are with 
suppurative adenitis and pneumonia[1]. Other common infections include liver 
abscesses, lung abscesses, osteomyelitis and septicaemia. These infections 
are severe and often result in hospitalisation for prolonged courses of treatment.  
Worldwide, there appear to be a relatively small number of organisms 
responsible for the majority of infections, although case reports of more unusual 
organisms have become more frequent in recent years. In America the most 
common organisms are: Staphylococcus aureus, Burkholderia cepacia, Serratia 
marcescens, Nocardia and Aspergillus species[3]. In the UK S. aureus and 
Aspergillus species are the most commonly isolated organisms, with only a few 
cases of Burkholderia, Nocardia and Serratia infection[1]. European data 
demonstrate similar findings to that in the UK with a striking paucity of 
Burkholderia infections[77]. Localised skin disease as a results of Bacille 
Calmette-Guérin(BCG) vaccination occurred in 24 patients. However, it was not 
clear how many had received BCG as protocols vary across Europe [77]. A 
review of 38 patients in Israel, where autosomal recessive disease is more 
common due to high rates of consanguineous marriage, demonstrated a wider 
range of infectious agents. S.aureus and Aspergillus were again the most 
frequent, but there were also significant numbers of Escherichia Coli, 
Salmonella, Candida albicans, Serratia marcescens, Pseudomonas and 
Burkholderia cepacia infections[87].  
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Rare organisms reported to cause infection in CGD patients include the fungus 
Geosmithia argillacea (causing pulmonary infection in seven cases in America 
and two in France)[113, 114] and bacterial osteomyelitis caused by 
Edwardsiella tarda in a 17 year old male in Japan[115]. 
Aspergillus nidulans infection appears an important indicator for CGD. Many of 
the case reports of A. nidulans infection on Pubmed involve patients with 
CGD[116-121]. It also appears to be more virulent and difficult to treat than 
Aspergillus fumigatus in people with CGD[122]. A recent review of Aspergillus 
osteomyelitis in CGD demonstrated 55% mortality for A.nidulans infection 
compared to 13% for A.fumigatus[123]. The cause for this remains unclear as it 
has been shown that, compared to Aspergillus fumigatus, Aspergillus nidulans 
is not killed by ROS dependent means in vitro. Studies have demonstrated that 
swollen conidia of Aspergillus nidulans are resistant to hydrogen peroxide in 
vitro, furthermore, A.nidulans conidia and hyphae are poor stimulators of 
ROS[124]. Blocking NADPH oxidase in polymorphonuclear leukocytes (PMNs) 
also had no effect on A.nidulans hyphal damage. PMNs and peripheral blood 
mononuclear cells from X-linked CGD patients inhibited germination and 
damaged A.nidulans hyphae as effectively as controls [124]. These findings 
contrast with those for A.fumigatus, where hyphal damage is significantly 
reduced by blocking NADPH oxidase and in cells from X-linked CGD 
patients[124]. 
It may be that invasive fungal infection has become less prevalent in recent 
years. The French CGD registry, which collected data from 2005-2009 reported 
an incidence of 0.04 invasive fungal infections per patient year[125]. However, 
the study used the 2008 European Organization for Research and Treatment of 
Cancer/Invasive Fungal Infections Cooperative Group and the National Institute 
of Allergy and Infectious Diseases Mycoses Study Group (EORT/MSG) 
definitions which were not available in the original study. It is not possible to 
determine incidence of fungal infection in the other registries as the data are not 
provided in a way which is comparable. The French group went on to look 
further at their proven mould infections. They identified 29 such infections in 24 
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patients, of whom only 54% were taking Itraconazole prophylaxis. In those that 
were taking prophylaxis, onset of fungal infection was later and  Aspergillus 
nidulans and other opportunistic moulds were more common than Aspergillus 
fumigatus[126]. Prognosis improved over time, but was also better in those that 
received prophylaxis. 
Tuberculosis may be more common in patients with CGD in endemic areas. A 
Chinese survey of 17 X-linked patients identified seven with tuberculosis, along 
with seven with abnormal scarring or abscess formation after BCG[127]. This 
was significantly higher than their background rate of childhood TB in the local 
population There is an increased risk of Mycobacterium avium infection as 
predicted using a mouse model which demonstrated increased risk of 
pulmonary infection (increased bacterial load) with M.avium and increased 
mortality compared to wild type mice inoculated with the same dose of 
M.avium[128]. There have been no published case reports of mycobactium 
avium in humans with CGD. 
1.7.2 Inflammation 
Inflammation is a significant component of the CGD phenotype. The typical 
inflammatory lesion is the granuloma (which gives CGD its name). Histological 
findings are of acute and/or chronic inflammation with fibrosis and non-
caseating granulomata[129]. These have a predilection for hollow viscera such 
as the colon, stomach and bladder. Although the finding of granulomas is 
considered pathognomic for CGD they are not always present. In many organs 
and tissues the most common finding is non-specific inflammation[129]. 
Gastrointestinal manifestations can mimic inflammatory bowel disease, affecting 
any part of the gastrointestinal tract. In some instances patients have been 
diagnosed with Crohn’s disease and treated as such before receiving a 
diagnosis of CGD[130] . A recent review of adult cases of CGD by Marks et al 
demonstrated histological features that would be consistent with a diagnosis of 
Crohn’s disease[131]. Oesophageal, gastric outlet and small bowel obstruction 
can occur. Colitis was seen in 37% of patients in the UK series[1] but in only 9% 
of the European patients[77]. Impaired growth is common.  In the UK series, 
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75% of those who had their height measured were below the population mean 
and 77% were below the mean for weight. Nasogastric nutritional support was 
required in 31% and a small number required total parental nutrition when 
acutely unwell[1]. Six patients in the series received growth hormone therapy for 
delayed growth. This information was not published in the European, Italian or 
American series so no comparisons can be drawn for different countries. 
Impaired growth may be related to poor nutrition as a result of bowel 
inflammation. However, in recent years it has been recognised that poor 
nutrition alone cannot explain impaired linear growth in Crohn’s disease and 
proinflammatory cytokines have a significant role to play[132]. This has not 
been explored in CGD. 
Urinary tract complications range from inflammatory cystitis to the development 
of urinary tract granulomata which can cause urinary frequency, as a result of 
reduction in bladder volume, through to ureteric opening or urethral obstruction 
in more severe cases. Ureteric opening obstruction can cause hydronephrosis 
with a resultant effect on renal function[133]. In the UK series, seven patients 
were found to have urinary tract granulomas[1].  
Along with frequent pulmonary infections, chronic lung disease is also found in 
CGD. In the UK series, 77% of those that had chest CT scans had significant 
abnormalities including bronchiectasis, obliterative bronchiolitic and chronic 
fibrosis[1]. A study of histopathology specimens from CGD patients 
demonstrated a variety of changes including granulomatous inflammation in 
40%, active neutrophilic inflammation in 40% and non-specific chronic 
inflammatory change with fibrosis in 11%[134]. However, both of these studies 
may over represent the changes as the patients underwent CT or lung biopsy 
for clinical indications.  
Ocular complications can also occur with CGD, particularly chorio-retinal 
abnormalities. In a small UK series, Goldblatt et al identified nine children out of 
38 who had Chorioretinal lesions on screening[135]. They described the typical 
lesion as a “punched out” lesion associated with pigment clumping lying along 
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major retinal vessels. The UK series by Jones et al also identified nine patients 
with chorio-retinal abnormalities, however, these may well be the same nine 
identified by Goldblatt et al. A series from Korea also frequently identified 
Chorioretinal lesions on screening, with six out of 17 patients affected[136]. This 
number compares to only 8 out of 368 in the American series reported as 
having chorioretinitis. However, this may reflect lack of screening at the time 
when data was collected. The significance of these findings has not been 
evaluated, Goldblatt et al describe the majority of lesions as “inactive”. 
However, 2 patients had significant visual impairment as a result of extensive 
lesions. It is unclear how much of an impact this had on these individuals. 
Skin rashes have also been described. these are typically Discoid Lupus 
Erythematosus(DLE) like but do not fulfil all the criteria for a diagnosis of 
DLE[137]. A case of acute neutrophilic dermatosis has also been 
described[138] as has dermatomyositis and leucocytoclastic vasculitis[139].  
A number of autoimmune conditions have been described, including: 
antiphospholipid syndrome; IgA nephropathy; juvenile idiopathic arthritis; 
idiopathic thrombocytopaenic purpura and myasthenia gravis[140, 141]. 
However, these are case reports and small series and whether these are truly 
linked to CGD is yet to be established. Until our understanding of the 
inflammatory mechanisms in CGD improves it will be difficult to develop clear 
hypotheses about the connection between these conditions and CGD. 
1.7.3 Haemophagocytic Lymphohistiocytosis 
Haemophagocytic Lymphohistiocytosis(HLH) is characterised by fever, 
cytopaenias, splenomegaly, hypertriglyceridaemia and low fibrinogen levels. 
There are a small number of cases of patients with CGD presenting with 
evidence of HLH, most commonly in association with infection[142, 143]. HLH 
results from an exaggerated immune response with secretion of excessive 
cytokines such as IL1, IL6, IL18 and TNFalpha. This perhaps represents the 
severe end of the hyperinflammation seen in CGD. 
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1.7.4 Malignancy 
There are reports of various malignancies in patients with CGD, including; 
lymphomas, leukaemia, retinoblastoma, rhabdomyosarcoma and 
glioblastoma[144-147]. In the 1980s it was suggested that hydrogen peroxide 
was required for neutrophil mediated tumor cell killing[148]. Therefore, it was 
hypothesized that CGD patients could be at increased risk of malignancy, 
however, this has not been reported in any of the large registries. 
1.8 Treatment 
1.8.1 Prophylaxis 
As described above, the first documented cases of CGD were fatal. Recognition 
and management of infections significantly improved life expectancy in the early 
years of the disease. Antibiotic prophylaxis became widespread from the late 
1970’s reducing the number of non-fungal infections[149]. Sulphamethoxazole-
trimethoprim(SMX-TMP) was identified as particularly useful for preventing the 
type of infections seen in CGD, a number of mechanisms were considered for 
this but it was established that, when compared with other antibiotics such as 
Penicillin, SMX-TMP had high levels of intra-cellular accumulation within 
leukocytes[150] . In 1983 Weening et al reported the safe and effective use of 
long term SMX-TMP in 9 patients, reducing the number of bacterial infections, 
reducing the need for surgical intervention and the number of days of 
hospitalisation per year[151].  In a description of the early European experience 
by Mouy et al in 1989, the introduction of prophylactic SMX-TMP significantly 
reduced the number of  bacterial infections (from 2.06 to 0.43 per year) and the 
need for surgical intervention, but did not affect overall survival due to a large 
number of deaths being related to fungal infection[152]. They also tried 
ketoconazole prophylaxis, but this had no effect on the Aspergillus infections 
that CGD patients commonly suffered.  
In the early late 1980s and early 1990s there was interest in the use of 
interferon gamma as a prophylactic agent due to its apparent ability to augment 
superoxide production[153]. A multicentre study showed a 70% reduction in the 
   
28 
 
number of infections in those receiving interferon gamma compared to the 
placebo group[154]. It therefore became common place to add interferon 
gamma in the United States. However, this was not adopted so widely in 
Europe, due to lower levels of serious infection compared to the American 
cohort it was trialled on[155], along with continued debate about its mechanism 
of action. It does not appear to up regulate NADPH oxidase activity[156] and 
there is a lack of evidence of effect when compared with Itraconazole 
prophylaxis. Long term follow up of 76 patients in America, from 1992 – 2001, 
suggested interferon gamma was well tolerated but serious infection rates 
continued at 0.3 per patient year for bacterial infection and 0.1 per patient year 
for fungal infection which were not dramatically different from rates in Europe 
where it was not being used[157].  An Italian retrospective study, as part of their 
registry, found no additional benefit when those receiving prophylactic interferon 
gamma were compared to those receiving standard antibiotic and antifungal 
prophylaxis[103]. Adverse effects from interferon gamma were also common, 
including fever, myalgia, headache and rash[103].Studies have failed to 
demonstrate improved neutrophil oxidative metabolism[158]. Only two patients 
in the UK registry received prophylactic interferon gamma[1]. In the European 
registry, 33% of patients received interferon gamma at some point, but this was 
not differentiated in to prophylactic and treatment groups[77]. More recently 
studies have suggested that only people with splice site mutations will benefit 
from interferon gamma therapy[159, 160].  
Itraconazole prophylaxis was introduced later than interferon gamma, but has 
become common place in Europe and America. Adding antifungal prophylaxis, 
in the form of Itraconazole, showed a significant reduction in the number of 
fungal infections in a randomised double-blind placebo controlled trial by Gallin 
et al in 2003. In the UK cohort 93% received antifungal prophylaxis[1], mainly 
Itraconazole, while in the wider European experience only 53% had received 
anti-fungal prophylaxis[77]. 
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1.8.2 Treatment of infections 
Aggressive and early use of antibiotics and antifungals remains the mainstay of 
treatment of infections in CGD. These are empirically directed against the 
organisms known to be problematic in CGD, while awaiting culture confirmation. 
Adjunctive therapies have included interferon gamma, granulocyte infusions 
and granulocyte colony stimulating factor in some cases. These are most often 
used for severe infections not responding to conventional treatment[1, 77]. 
White cell infusions have, perhaps become less commonly used, with the 
development of better antifungals as there are associated risks, such as 
alloimmunisation to HLA class I antigens and the risk of Cytomegalovirus 
infection, which could complicate any later HSCT[161]. Surgery may be 
required for drainage of abscesses or removal of consolidated areas of infection 
that will not respond to antibiotics alone[133]. 
1.8.3 Treatment of inflammatory complications 
Inflammatory components of CGD, for example bowel disease or obstruction of 
the GI or genitourinary tract, require immunosuppressive agents. The most 
commonly used agents are corticosteroids, however the benefits have to be 
weighed against the increased risk of infection. In particular, high dose steroid 
use has been associated with the development of mucormycosis in CGD 
patients[162]. The use of corticosteroids was first reported in 1987, for 
gastrointestinal and genitourinary granulomata causing obstruction[163]. 
Corticosteroids are also effective for granulomatous cystitis[164]. However, 
symptoms may recur on weaning and long term low doses may be 
required[133]. CGD colitis is often managed in a similar fashion to Crohn’s 
disease, with 5–aminosalicylates (5ASA), steroids and, more recently, the 
Tumour Necrosis Factor alpha blocking agent Infliximab[3, 130, 165]. The 
review by Marks et al identified some response to 5-aminosalicylates, 
thalidomide and interferon gamma, with better response to azathioprine, 
infliximab and surgical resection. None of their patients responded well to 
steroids[131]. Infliximab has been useful in treating refractory colitis. However, 
there are concerns about increasing rates of infection in these patients, despite 
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continuing antimicrobial prophylaxis. Five American patients treated with 
infliximab, along with 6-Mercaptopurine, prednisolone and 5ASA compounds 
developed serious infections with Burkholderia, Staphylococcus, Candida and 
Aspergillus species[166]. A literature review of 17 published cases (11 
autosomal recessive) where TNF alpha blocking agents (Infliximab, Etanercept 
or Adalimumab) were used demonstrated sustained improvement in only five 
cases but also raised concerns about increased serious infection risk as seven 
developed serious infection after use of TNF alpha blocking agents[167]. The 
interleukin-1 antagonist, Anakinra, has also been successfully used, due to 
fewer concerns about infectious complications[168]. 
Recent work in macrophages, from gp91phox deficient mice, has raised an 
interesting question about the use of interferon gamma for suppression of 
inflammation in CGD. It was demonstrated that priming with interferon gamma 
enhanced the uptake of apoptotic neutrophils by macrophages, which may 
contribute to a reduction in the inflammation seen in CGD[169]. 
1.8.4 HSCT 
Stem cell transplant is now an attractive option for CGD as it can provide a 
complete cure. However, early attempts in the 1970s and early 1980s were 
essentially unsuccessful,  with only one child out of five surviving with 
reasonable donor engraftment [170]. In America in the 1990s non-myeloablative 
T cell depleted HLA identical sibling transplants were attempted in 10 patients 
with 70% survival. Of these, two rejected their transplant and three of the four 
adults with donor engraftment developed acute Graft versus Host Disease 
(GvHD)[171]. From then there has been significant improvement. The European 
experience from 1985-2000 demonstrated 81% survival with complete cure 
using a more aggressive approach than the Americans, with myeloablative 
conditioning and unmodified haematopoietic allograft [172]. Over recent years 
there has been an improvement in survival following HSCT for many primary 
immunodeficiencies[173]. This results from a combination of factors including 
development of less toxic chemotherapy regimes, better recognition and 
management of infections and improved treatment of GvHD. Improvements in 
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transplant techniques have led to improved survival and disease cure with both 
matched sibling donors and unrelated donors for CGD[2, 172, 174]. Long term 
outcome has also been good, with a recent series of 20 patients from a single 
centre in the UK showing 90% survival with normal neutrophil function, 
remission of colitis and good catch up growth[2]. Concerns have persisted 
about the use of myeloablative conditioning in patients with significant infections 
or inflammatory complications. However, recent experience with a reduced 
intensity conditioning regime has resulted in a good outcome in older patients 
with a number of severe disease related complications[175], which may provide 
hope of a cure for those that were previously deemed too unwell for HSCT . 
HSCT has also recently been advocated for the treatment of people with severe 
bowel disease associated with their CGD, when conventional treatment fails or 
side effects are too severe[176]. 
There are potential long term complications of HSCT which have yet to be 
evaluated in children who have undergone transplants for immunodeficiency, 
including CGD. Late effects are well recognised in transplants for malignancy. 
These include, secondary malignancy, endocrine disorders, particularly thyroid 
dysfunction, and organ specific complications such as bronchiolitis obliterans 
and avascular necrosis of the femoral head[177]. Many of these complications 
are related to the use of total body irradiation and long term steroid use for 
chronic graft versus host disease which are not normally factors in transplant for 
children with CGD[178]. Gonadal failure and infertility are also a particular 
concern following HSCT. Again, infertility is associated with irradiation but also 
busulphan and cyclophosphamide conditioning regimes, which are used in CGD 
transplants. Sanders et al demonstrated that the partners of 24% male patients 
who had received cyclophosphamide but only 4% of those who had received 
busulphan and cyclophosphamide became pregnant. However, these were 
transplants for malignancy and aplastic anaemia in children over the age of 12 
at transplant[179]. There has been no evaluation of fertility after HSCT in 
childhood for CGD as there is currently not long enough follow up. 
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 In post-pubertal males undergoing HSCT there is the option for storage of 
sperm pre-transplant, which may give them the potential to father children later 
in life. This is obviously not an option for children who undergo transplant before 
puberty and is therefore an issue that families may wish to consider when 
thinking about the best time for their child to undergo HSCT. However, there is 
also the issue for men with X-linked CGD regarding potential transmission of 
their inherited disease, which is not present in those treated for malignancy. 
Males with X-lined CGD, including those who have undergone HSCT, can have 
healthy male children, but female children will be carriers, with the potential to 
have an affected child themselves. This may make the issue of whether to have 
children a very difficult decision for individuals. 
1.8.5 Gene therapy 
Similar to HSCT, gene therapy has been tried for CGD. In principle it appears a 
good option, as CGD is the result of a single gene defect, and incomplete 
correction will still eliminate symptoms. Unfortunately however, gene therapy 
has not seen particularly successful results to date. Gene corrected cells in 
CGD patients do not show a growth advantage over diseased cells as seen in 
patients with severe combined immunodeficiency treated with gene therapy. 
This results in very low numbers of the corrected granulocytes appearing and 
remaining in the peripheral blood long term[180]. Better results have been 
obtained if patients receive myeloablative conditioning but, as in HSCT, this has 
risks attached, such as herpes virus reactivation which could be fatal. There are 
also concerns about the potential development of leukaemia as has been seen 
in X-linked SCID patients treated with gene therapy[181]. This has not been 
found to date in CGD patients but clonal expansion of the modified cells has 
been found[180]. A report published in 2010 of two cases of CGD treated with 
gene therapy demonstrated vector inactivation of gene transduced cells, which 
then had no microbicidal activity. They also demonstrated clonal expansion and 
increased genetic instability, with myelodysplasia. One patient died of 
overwhelming sepsis 27 months after gene therapy and the other was treated 
with HSCT[182]. With the current concerns about gene therapy it is currently 
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mainly used as rescue therapy, to treat severe infections which are refractory to 
conventional management, with the expectation that it will not be curative but 
will prevent death from the immediate infection[183, 184]. 
There are a number of advances that may make gene therapy a more attractive 
option in the future. Recent work in mice has suggested it may be possible to 
develop lineage and stage restricted vectors, targeting only fully differentiated 
mature phagocytes, so preventing the risk of mutagenesis[185]. Another option 
appears to be the use of patient derived induced pluripotent stem cells (iPSCs) 
to generate functional neutrophils. The potential for this technique has been 
demonstrated to work in mice[186] and in human cells[187]. In theory it would 
be possible to use gene corrected iPSCs to create functional neutrophils that 
could be infused in to a patient, for example to treat refractory infection. This 
would have fewer risks than current strategies as the mature neutrophils would 
not have the ability to engraft or proliferate, so preventing the risk of 
myelodysplasia and malignancy.   
1.9 Prognosis 
CGD is no longer fatal in early childhood, but remains a life limiting condition. 
Data from the UK series demonstrated 88% survival at 10 years, but only 55% 
survival at 30 years[1]. The Italian series identified similar trends in survival, 
with 46% still alive 25 years after diagnosis[103]. Perhaps surprisingly, these 
figures do not appear to have improved significantly over recent years, despite 
presumed better recognition and management of the disease. Finn et al 
reviewed UK CGD patients from 1964-1989 and, similar to Jones et al,  
identified 50% mortality by the third decade[188]. Fungal infections have 
continued as an important cause of death, Aspergillus being particularly 
prominent. Aspergillus infection was the cause of death in 50% of the Italian 
cases and 15 out of 84 deaths in van den Berg et al’s paper on the European 
experience [77, 103]. Survival was significantly reduced in the French cohort for 
those that had invasive fungal disease compared to those that did not[125]. 
Given that many patients now take anti-fungal prophylaxis it is difficult to say 
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why mortality remains so high. The causative organisms continue to be similar 
and should be sensitive to the azoles. There are few reports of azole resistance 
in CGD, one such report was for a patient treated over a two year period for 
aspergillus pulmonary infection with combination azole and echinocandin 
therapy, who developed resistant isolates on treatment[189]. None of the 
registries reported Itraconazole levels so it is difficult to tell whether patients 
were taking the prescribed prophylaxis. Other infectious causes of death have 
included Candida species, Burkholderia cepacia and Salmonella[77, 103]. Non-
infectious causes of death described by van den Berg et al included: cardiac 
failure, chronic lung disease and malignancy[77]. Non-cirrhotic portal 
hypertension appears to have an important association with mortality in 
infectious episodes, with thrombocytopaenia, raised alkaline phosphatase levels 
and history of liver abscess all being independent predictors of mortality[190].  
For those that live with CGD there is continued morbidity, with frequent 
infections requiring hospital treatment and long term growth failure.  
Given the long term complications of the disease, one could argue that curative 
treatment should be advocated. However, there is not insignificant mortality 
associated with HSCT. Four out of 27 CGD patients that underwent HSCT died 
in Seger et al’s paper on the European experience. These were all patients with 
pre-existing therapy-refractory fungal infection, which increases the risk of 
transplant[172]. Two out of 20 died in Soncini et al’s paper, one during 
chemotherapy conditioning for HSCT as a result of overwhelming fungal 
infection and the other 73 days after transplant from haemorrhage, as a result of 
arterial erosion by a tracheostomy tube[2]. Currently, gene therapy remains 
experimental as there are still questions about its effectiveness and safety to 
answer before it can be used routinely. Therefore, families are left with a difficult 
decision, to risk the complications of HSCT or gene therapy, or live with the long 
term complications of CGD and expect the sufferer to have a reduced life 
expectancy. 
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1.10 Quality of life in Chronic Granulomatous Disease 
As detailed above, patients with CGD have wide variety of infective and 
inflammatory complications. They can spend a large amount of time in hospital 
and have difficulties maintaining normal, everyday activities. From discussion in 
clinic appointments, there is anecdotal evidence of the impact this disease has 
on children and families. For example, those who give up their favourite sport as 
they feel embarrassed to get changed in front of their peers because they are 
short and not as physically mature. Or, those who can not go away on trips with 
school or friends because of the need to go to the toilet on a frequent basis. 
There are also restrictions placed on a child’s activities in order to avoid 
infection, for example, the need to avoid playing outside in fallen leaves or wood 
chip due to the risk of fungal infection. There can also been an impact on 
schooling, with the need to avoid building work which can result in a child not 
being allowed in certain classrooms and potentially being isolated from their 
peers. There is also stress for the family caused by the knowledge that the child 
is living with a life limiting condition and maternal guilt about transmission of a 
genetically inherited disease. 
Clinicians recognise from their interactions with these families that these issues 
are likely to have an impact on the patient’s quality of life, their emotional 
wellbeing and their self esteem. The degree of impact the diagnosis of CGD has 
on quality of life, emotional well being and self esteem is likely to vary with a 
child’s age and maturity, depending on their understanding of their condition 
and the degree of impact it has on their daily life. For example, it would seem 
likely that a teenager with a good understanding of their diagnosis and growth 
retardation due to colitis is likely to be more affected than a five year old, who 
has been relatively well, perhaps only in hospital with one infection and has little 
understanding of their condition. However, none of this has been formally been 
studied in CGD. 
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1.11 Quality of life in chronic disease 
Quality of life has been defined by the World Health Organisation (WHO) as: 
A individual’s perception of their position in life in the context of the culture and 
value systems in which they live, and in relation to their goals, expectation, 
standards and concerns[191]. 
An individual’s state of health can impact on their quality of life. 
Where the WHO defines health as: 
A state of complete physical, mental and social well-being – not merely the 
absence of disease or infirmity[192] 
Health related quality of life (HRQOL) is a concept that has evolved over recent 
decades to include aspects of quality of life connected with physical and mental 
health, including: health perceptions, functional status, social support and 
socioeconomic status[193]. Tools have been designed to measure HRQOL and 
it has become a recognised outcome in a wide range of research. HRQOL 
measures can be generic or disease specific. They are usually self-report 
questionnaires, as doctor’s and patient’s opinions do not correlate well, with 
clinicians rating a patients quality of life as poorer than the patient would 
themselves[194].  
Chronic illnesses can result in poor quality of life in children and adults with a 
variety of conditions. For example, poor HRQOL has been documented in sickle 
cell disease, juvenile idiopathic arthritis and rare genetic conditions[195-199]. 
However, not all individuals with a disease or disability will rate themselves as 
having poor quality of life. Therefore, it is not possible to draw conclusions for 
patients with CGD without measuring it. A study of children with chronic kidney 
disease demonstrated higher quality of life scores for those with kidney disease 
compared to the normal population[200]. The authors concluded that the 
patients had successfully adapted to their diagnosis, rather than lowering their 
expectations of what they could achieve, indicating a true good quality of life.  
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Children often rate their quality of life better than their parents[201, 202]. This is 
thought to be because the children do not know anything different, whereas, 
parents are comparing their situation to other healthy children. Some research 
has been undertaken to evaluate whether it is possible to predict quality of life. 
In juvenile idiopathic arthritis the predictive factors have been demonstrated to 
be: functional ability, pain, subjective burden of medication and school 
absence[199]. However, disease severity does not necessarily correlate well 
with quality of life. A study in children with asthma showed quality of life was 
predicted by associated emotional and behavioural problems but not disease 
severity[203]. A study of children with JIA demonstrated impaired quality of life 
in children with minimal symptoms or even no symptoms[204]. 
Advances in medical treatments have resulted in improved survival for people 
with many chronic or life threatening conditions. As a result of this there has 
been an increased interest in the presumed improved quality of life provided by 
these treatments. HSCT has been demonstrated to have a positive impact on 
quality of life in children, although there is a drop immediately after the 
procedure there is a gradual increase from that point onwards[205, 206]. 
However, this work has mainly been done in paediatric haematology/oncology 
transplants where HSCT is rescue therapy for conditions with dramatically 
reduced life expectancy. There are no studies looking at quality of life in 
children undergoing HSCT for primary immunodeficiencies. There has been one 
study looking at quality of life in the primary immunodeficiency  X-linked 
agammaglobulinaemia, which showed poorer quality of life compared to healthy 
controls, but not as bad as quality of life in children with rheumatological 
diagnoses. However, this group of patients do not undergo HSCT[207]. There 
has been a study of social functioning (an element of quality of life) in children 
treated with HSCT for primary immunodeficiency which included a small 
number of CGD patients (3% of the sample). This demonstrated impaired social 
functioning, with difficulties in peer relationships, fewer friends and being more 
likely to play alone when compared to healthy controls[208].  
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As has been discussed, it is not possible for clinicians to determine the quality 
of life of patients with CGD without measuring it. For it to be valid, it is 
necessary to undertake an assessment of patient/parent perspectives on quality 
of life not clinician ratings. 
1.12 Emotional disorders in chronic disease 
1.12.1 Psychological adjustment to chronic disease 
Diagnosis of any chronic disease will impact upon a child and their family, as 
they are confronted with new challenges, for example, dealing with symptoms, 
limitations to their activities and the administration of treatments. Patients and 
families must find ways to cope with, and adjust to their new circumstances. 
The effects of diagnosing a chronic disease in a child are wide ranging, 
impacting on physical well being but also education, social relationships and 
emotional well being, along with family finances[209]. 
Studies in adults with chronic illness have shown adjustment is most successful 
when patients can maintain emotional balance, preserve healthy relationships 
and maintain a good functional status, for example continuing to work[210]. 
However, approximately 30% of adult patients have a prolonged or 
unsuccessful adjustment to their new situation[211]. There are many factors 
which influence adjustment. A study in children with type 1 diabetes mellitus 
showed characteristics such as age, sex, socioeconomic status, ethnicity and 
family environment can all have an impact on adjustment[212]. Abnormal 
psychological responses in this group include depression, anxiety, stress, 
behavioural disorders and eating disorders. Positive adjustment was associated 
with effective coping strategies, positive family functioning, good self 
management skills and social competence[212]. 
1.12.2 Emotional disorders in children with chronic disease 
A meta-analysis of 87 studies of psychological adjustment to a diagnosis of a 
physical disorder, has shown children are at risk of psychological adjustment 
disorders such as depression, anxiety and stress[213]. A large epidemiological 
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study in Canada has shown children with chronic illness are at increased risk of 
a whole range of psychological disorders including: anxiety, depression, 
obsessive-compulsive disorder, conduct disorders and attention deficit 
hyperactivity disorder[214]. An even larger population study of nearly 12,000 
children and adolescents, with a range of chronic conditions, in America also 
demonstrated an increased risk of behavioural problems, such as peer conflict 
and social withdrawal[215]. Social adjustment can also be affected.  The 
Canadian study showed children with chronic conditions with associated 
disability (measured by limitations of normal function) had difficulties getting 
along with peers, were more isolated, had low participation in activities and low 
competence[214]. This was not true for those with chronic conditions without 
associated disability. It may be, however, that these findings are due to physical 
restrictions impacting on ability to be involved in activities with their peers. 
Data from the original UK CGD registry demonstrated increased emotional 
difficulties, as reported by their parents, in children with CGD compared to the 
normal population when evaluated with the Strengths and Difficulties 
Questionnaire[6]. 
In recent years, it has been recognised that depression has a significant 
inflammatory component. Various markers of inflammation have been shown to 
be raised in people with depression, including: C-Reactive Protein, interleukin-1, 
interleukin-6 and tumour necrosis factor alpha[216-218]. Work in adults 
receiving haemodialysis has shown a correlation between IL6 levels and anxiety 
symptoms but not depression[219]. They also demonstrated inverse correlation 
between quality of life and levels of IL6, IL10 and TNF alpha. 
Rates of depression have not been evaluated in people with CGD. It could be 
hypothesised that depression will be common, not just because of the 
implications of living with a life limiting disease, but also because CGD induces 
a hyperinflammatory state, which could itself induce depression.
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1.13 Self esteem in patients with chronic disease 
Self esteem is defined as: 
An individual’s self perception of his/her abilities, skills and overall qualities that 
guides and/or motivates specific cognitive processes and behaviours[220] 
Harter argues that by the age of eight years, children have a view of their self-
worth which is broader than their competencies in specific skills, for example, 
physical activities[221]. Physical appearance is an important predictor of global 
self worth[222]. Scholastic competence appears to become more important as 
children get older. A small study from Northern Ireland demonstrated that at age 
eight years social acceptability was second after physical appearance, but at 
eleven years old scholastic competence was second most important[222]. 
Self esteem can be affected by chronic illness. Low self esteem can result in 
depression, difficulty managing stress, poor social relationships and perceived 
worsening of symptoms, so having a significant impact on the quality of life of 
patients[220]. However, in one study of adolescents, those with chronic 
illnesses scored higher self esteem and lower stress than controls[223]. It has 
been argued that these children look to things other than physical health to 
provide value and meaning to their life. There has been no evaluation of self 
esteem in those with CGD. 
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1.14 Intelligence and Chronic Illness 
Intelligence (IQ) can be difficult to define and continues to provoke much debate 
regarding its worth.  
It has perhaps best been described in an editorial signed by 52 American 
academics as: 
A general mental capability, that among other things, involves the ability to 
reason, plan, solve problems, think abstractly, comprehend complex ideas, 
learn quickly and learn from experience[224]. 
Many would agree that it is beneficial to consider (and measure) intelligence as 
it is associated with educational, occupational, economic and social 
outcomes[225]. It appears to be a predictor of long term survival in the general 
population. An association between childhood IQ and all cause mortality in 
adulthood has been described. A study from Scotland for children born in 1921 
and in school in 1932 showed those with lower scores on the mental ability test 
were less likely to be alive in 1997[226]. However, a cohort from the North East 
of England identified a correlation between IQ at age 11 and mortality up to 
middle age (56 years) in men, but not in women[227]. The reasons for this 
association are complex and may be connected to those with higher IQs making 
healthier lifestyles choices and making better use of health care services. 
Low IQ has been identified in a number of chronic illnesses, both with and 
without obvious neurological involvement, for example: multiple sclerosis[228], 
schizophrenia[229], chronic kidney disease[230] and inflammatory bowel 
disease[231]. This is important because it has the potential to impact on the 
health of patients, in terms of understanding their disease, making decisions 
about treatment options and complying with treatment (those with higher verbal 
IQ are more likely to comply with long term medication[232]) 
In recent years it has been demonstrated that inflammation is associated with 
cognitive decline and the development of dementia in the elderly[233, 234]. 
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Increased levels of the non-specific inflammatory markers C-reactive protein 
(CRP) and the Erythrocyte sedimentation rate (ESR) have been shown to be 
associated with poorer cognitive function in adults[235, 236]. This association 
has even been demonstrated in adults as young as 18-20 years old, where ESR 
was inversely correlated with performance on an IQ test. However, this study 
did not identify causes for raised ESR and may have included those with acute 
infection, as well as on going inflammatory conditions[235]. Acute infection has 
been shown to alter cognitive function. A small study of 12 humans were 
administered a low dose of Escherichia coli endotoxin. They had TNF alpha and 
IL-6 levels measured at intervals after administration and were also asked to 
perform neuropsychological tests before and after administration of the 
endotoxin. This showed inverse correlation between circulating IL-6 levels and 
memory function, although not overall cognitive function[237]. 
There has also been a lot of interest in Interleukin 1 beta (IL1 beta), a pro-
inflammatory cytokine which is expressed in the brain[238]. IL1 beta has been 
implicated in postoperative cognitive decline in the elderly[239]. In a mouse 
model of orthopaedic surgery (as a trigger of inflammation) memory impairment 
was demonstrated which was interleukin 1 dependent.  IL-1 receptor knock-out 
mice, and mice treated with an IL-1 antagonist did not demonstrate the same 
memory impairment[239]. Another mouse model with hippocampal IL-1 beta 
over expression demonstrated impaired long term contextual and spatial 
memory when exposed to various fear conditioning experiments[240]. 
There is evidence that IQ can improve after certain solid organ transplants. In a 
study of children undergoing kidney transplant for end stage kidney disease, a 
group known to have neurocognitive deficits[241], IQ improved by a mean of 12 
points after transplant compared to a group who had not received 
transplant[242]. This took the post-transplant group from the borderline to the 
low normal range. Although not evaluated, it could be hypothesised that this 
may help in patient compliance with their long term immunosuppression as well 
as having social and economic benefits. 
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1.14.1 Cognitive deficits in CGD 
One small American study of 26 patients identified cognitive deficits in the X-
linked CGD population, with  6 (23%) having an IQ less than 70, which is 
markedly below the normal range and will have an impact on educational and 
work performance[5]. The authors suggested the lower than expected IQ could 
be due to frequent illnesses and hospitalisations. However, this has not been 
seen in other chronic illnesses such as cystic fibrosis[243], a condition that 
would cause a similar pattern of frequent infections and hospital admissions. 
They, therefore, proposed other possible mechanisms related to the lack of 
superoxide production in CGD, including abnormal development of neurons and 
abnormal signalling within cerebral pathways[5]. Other proposed mechanisms 
include frequent brain infections or dysregulation of inflammatory 
processes[129]. However, the data from this study need to be interpreted with 
care as all of the patients had already been referred to neuropsychological 
services for educational or behavioural concerns and may not therefore reflect 
the true population of people with CGD.  
There has also been some work in CGD mouse models (both gp91 and p47 
phox deficient mice) which demonstrated impaired memory, thought to be due 
to lack of ROS as signalling molecules [244].NADPH oxidase is required for N-
methyl-D-aspartate (NMDA) receptor dependant signalling through activation of 
extracellular signal-regulated kinase (ERK) in the hippocampus. In mice NMDA 
receptor dependent activation of ERK can be blocked by diphenylene iodonium, 
an NADPH oxidase inhibitor, and is also absent in p47phox deficient mice[245]. 
Blocking signalling impairs long term potentiation which is a mechanism 
associated with memory formation. In the mice this resulted in impaired spatial 
memory in those that were gp91phox deficient and impaired context dependent 
fear memory in those that were p47phox deficient[244]. The authors of this work 
suggested there may be mild cognitive defects in patients with CGD based on 
their work in mice. This has not been evaluated in detail.  
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Another area which has not been evaluated in CGD patients is the possible link 
between high levels of IL1 beta (which have been found in CGD[55]) and the 
cognitive decline and memory impairment as discussed above. 
There has been one study looking at cognitive deficits and behavioural 
abnormalities in children undergoing HSCT for severe congenital 
immunodeficiencies, which included two patients with CGD[4]. This concluded 
that children undergoing HSCT for primary immunodeficiency were more likely 
to have cognitive deficits and behavioural abnormalities when compared to 
sibling controls. However, specific analysis was not carried out for the CGD 
patients as the numbers were so small.  It is also important to recognise that 
this group included children with a diagnosis of adenosine deaminase deficient 
severe combined immunodeficiency, which has previously been shown to be 
associated with low IQ and increased behavioural difficulties and may have 
therefore influenced the sample results[246]. There have been no other 
published studies on cognitive factors in CGD patients undergoing HSCT. 
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1.15 Summary 
Since the UK and Ireland CGD registry was compiled initially in 2000[1] there 
has been no further large scale study in this country looking at the prevalence, 
clinical features and mortality for CGD. Although rare it remains an important 
condition due to the high level of medical input required by each patient. There 
have been significant advances in management of the condition, including 
improved outcome from HSCT and further developments in gene therapy. This 
has led to improved survival and complete cure for some. It is not clear whether 
there has been an increase in survival for those treated conservatively. There is 
an increased awareness and interest in quality of life in primary 
immunodeficiencies, as other chronic conditions and the process of HSCT have 
both been shown to impact on life quality. There have also been questions 
raised about the cognitive function for people with CGD following the publication 
of the paper by Pao et al, as described in section 1.13.1[5].  
Since issues of physical and mental health are interlinked it was appropriate to 
gather further clinical information on people with CGD in the UK and Ireland and 
look at their psychological wellbeing and cognitive function at the same time.  
This information is vital for individuals with CGD, in terms of making the 
decision about whether conservative or curative management would be the best 
option for them. It is also important for the health services in order to better 
understand the current health needs of those with CGD and plan for appropriate 
service provision. 
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Chapter 2 Study Objectives & Hypotheses 
The objectives of this study were to: 
1. Survey the clinical course, treatment and mortality of children with CGD in 
the UK and Ireland, through an updated registry of CGD patients.  
2. To compare rates of infection, admission and surgery in non-HSCT and 
post-HSCT children. 
3. Evaluate cognitive function in children with CGD, comparing those that have 
and have not undergone curative treatment. 
4. To document quality of life and emotional wellbeing in children with CGD 
and compare those who have and have not undergone HSCT. 
 
The hypotheses for this study were: 
 
1. Children with CGD have more infections, surgery and admissions to hospital 
than those who have undergone HSCT. 
2. Children with CGD have impaired cognitive function, as demonstrated 
through lower than expected IQ test scores. 
3. Children with CGD have poor quality of life, increased emotional and 
behavioural difficulties and poor self esteem compared to normal, healthy 
children. 
4. Children who have undergone HSCT for CGD will have better quality of life, 
emotional wellbeing and self esteem compared to those who have not 
received HSCT. 
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Chapter 3 Methods 
3.1 The UK and Ireland CGD registry 
Disease registers, or registries, are a well recognised way of gathering clinical 
information for a variety of purposes. The terms are often used interchangeably. 
The definition according to the Dictionary of Public Health is: 
Register, registry     A data file containing information about all the identified 
cases of a condition, such as cancer, ideally in a region (state, province, or 
nation) with a defined population. The information should include age, sex, 
other pertinent identifying data such as occupation and place of residence, and 
precise diagnosis.…..Preferably a registry should provide statistically compiled 
data on all identified cases in a specified jurisdiction with a defined population, 
so that rates and prevalence can be calculated, but registries are useful even 
without a defined population because case fatality and survival rates can be 
calculated for the populations in specified diagnostic categories[247]. 
According to a report commissioned by the Department of Health Policy 
Research Programme for the White Paper Saving Lives: Our Healthier Nation, 
registers are databases that attempt to identify all cases of a disease in a 
defined population[248]. Registers are particularly useful for gathering data on 
rare diseases[249]. In a review of disease registers in England published in 
2002 approximately 250 were identified, covering a variety of different 
conditions, such as cancers, diabetes, congenital anomalies and more specific 
diseases such as; Galactosaemia, Gaucher’s and Fabry’s diseases[248] .  
In 2008 Jones et al published data from the UK and Ireland CGD registry, 
compiled in 2000-2001[1]. It attempted to identify all CGD patients in the UK 
and Ireland who were alive and diagnosed before 31st December 2001. Medical 
specialties that might care for CGD patients were determined and 1684 
physicians were contacted in an attempt to identify all cases of CGD within the 
UK and Ireland. Those that reported having CGD patients were provided with 
information packs and consent forms for participants to enrol in the registry. 112 
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patients fulfilled inclusion criteria for the registry and 94 were enrolled. Detailed 
data were collected from medical records and death certificates obtained from 
the Office of National Statistics. This provided comprehensive information about 
the majority of patients with CGD in the UK and Ireland at that time. Due to the 
design, this study was successful in finding the majority of people with CGD 
rather than just those limited to large centres. The Italian and European 
registries only requested information from primary immunodeficiency network 
members and specialist diagnostic laboratories respectively, so potentially 
missed patients cared for in local hospitals only[77, 103]. The UK and Ireland 
Registry gathered very wide ranging clinical information, as the research team 
abstracted the data, rather than relying on local physicians to complete the 
forms. It was also able to collect information regarding people with CGD who 
died before referral to a specialist centre by collecting data from the Office of 
National Statistics regarding cause of death. Some additional updates were 
added to the Registry up to 2004. The registry is held within Newcastle 
University and is the basis for the current update. 
3.2 Study population 
This study aimed to recruit participants from across the entire UK and Republic 
of Ireland. Ninety-four patients were consented for the previous registry. It was 
not known exactly how many people were living with CGD in the UK and 
Ireland, as the previous registry was only able to provide a snapshot of 
prevalence up until 1999. Using the European Commission’s Eurostat data 
which provides information on total number of live births in the UK for the 
decade 2000-2009 as 7,253,564 and the total number of births in the Republic 
of Ireland for 2000-2009 as 643,984[250] and Jones et al’s birth prevalence of 
7.5 cases per million it is possible to estimate the number of new cases 
between January 2000 and December 2009 as 59 (presuming the birth 
prevalence has remained the same). Jones et al also showed a mortality of 
12% over 10 years. Therefore, it could be estimated that there would be 
approximately 150 people, both children and adults, living with CGD currently 
(from the 112 previously found and 59 estimated new cases).  
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3.3 Participant identification 
Information from the original CGD registry was accessed and consultants that 
previously acknowledged that they were caring for patients with CGD identified. 
Those patients included in the original registry that would still be under 16 years 
of age at the commencement of this study (i.e. with birthdays after 1st June 
1994) were identified. 
The study was advertised by circulating information through a variety of special 
interest groups across the UK and Ireland, asking members to respond, 
identifying whether they had any CGD patients currently, or had previously had 
patients that had since died. These groups included: The British Paediatric 
Allergy, Immunology and Infection Group (BPAIIG), The Travellers (adult 
immunologists), The British Society for Paediatric Gastroenterology, Hepatology 
& Nutrition, The British Society for Gastroenterology, The British Society for 
Haematology, The British Paediatric Respiratory Society, The British Thoracic 
Society and The British Infection Association. 
Two major centres for the care of paediatric patients with CGD have evolved 
since the registry was developed, one being Newcastle. Great Ormond Street 
Hospital is the other and has specific monthly CGD clinics for patients from the 
south of the UK. 
Other centres with smaller cohorts of paediatric CGD patients were also 
identified and approached. These were identified from the original registry, from 
knowledge of teams at the two main centres and from the CGD Research Trust 
nurse specialist, based at Great Ormond Street. Centres were asked to confirm 
whether they had patients and whether they would agree to collaborate. 
3.4 Case definition 
Children, under the age of 16 years, with a confirmed diagnosis of CGD on NBT 
or flow cytometry, with or without protein expression abnormalities or identified 
genetic mutations, were eligible for the study.  
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3.5 Exclusion criteria 
Individuals were excluded if they were not usually resident within the UK or the 
Republic of Ireland but had attended a UK centre for part of their treatment, for 
example HSCT. Children were excluded from the IQ test if they were under the 
age of 5 years as the WASI assessment is not appropriate for this age group. 
Those participants for whom English was not their first language were excluded 
from the standardised quality of life and psychology questionnaires if they were 
deemed not to be able to complete the questionnaires in English. They were 
included in the registry update (gathering of clinical information from their 
records) if they are able to provide consent. 
3.6 Ethical approval 
A favourable opinion was provided by the County Durham and Tees Valley 1 
Regional Ethics Committee (09/H0905/73). Section 251 approval was obtained 
from the National Information Governance Board Ethics and Confidentiality 
Committee for access to records of patients in England and Wales that were 
deceased and therefore unable to consent for the study. Site specific research 
and development approval was obtained for each hospital with patients. 
3.7 Recruitment and informed consent 
Following appropriate ethical and research and development approval potential 
participants were provided with age appropriate information leaflets by the team 
of healthcare professionals looking after them or the study principle investigator 
(i.e. the author). This was either done in person at their routine clinic 
appointments or by post. Information leaflets were available for parents, 
children aged 6-10 years and 11-15 years. 
Written consent was obtained from parents for living participants under the age 
of 16. The children were given the opportunity to complete written assent if they 
wished. The consent form gave parents the option to be included in all parts of 
the study or to choose not to complete the psychology questionnaires or the 
   
51 
 
WASI IQ test if they preferred. Those that were included in the original registry 
were re-consented for the new round of data collection as well as the 
psychology components of the study. 
Each participant’s General Practitioner (GP) was informed of their patient’s 
involvement in the study. 
Deceased patients were identified by clinicians. Their notes were accessed for 
addition of data to the registry following NIGB section 251 approval. Families of 
deceased patients were not approached as it was deemed likely to cause 
unnecessary distress to families to ask for permission to access their family 
member’s records. 
Consultants were asked to provide gender and age for those that did not 
consent to involvement in the study in order to calculate birth prevalence. 
3.8 Evaluation of clinical data 
3.8.1 Birth prevalence 
Dates of birth/ages were used to calculate numbers of children with CGD born 
in the last 3 decades (1990s, 2000s, 2010 onwards). Data were available for 
live births in the UK and Ireland for decade 2000-2010.  
Observed birth prevalence for  2000-2010 was calculated as: 
Number of children born with CGD/number of live births UK + Ireland 
3.8.2 Clinical outcome 
For those patients that consented to involvement in the registry, medical 
records were accessed. Data were abstracted using a standard proforma to 
provide up to date clinical information on the problems commonly associated 
with CGD (Appendix 1 contains details of information collected on the proforma, 
although not the proforma itself as this was 44 pages long). Data included: 
growth, respiratory and gastrointestinal symptoms, infections, hospitalisations, 
medications, surgery and other complications or treatments received including 
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HSCT or gene therapy. Dates of specific events, hospitalisations, infections etc 
were documented where possible. If exact dates were unclear from medical 
records the closest possible estimate was made. For example, if an exact date 
of commencing a medication could not be determined the 1st of the month it was 
started in would be used. If the month was also unclear the date would be 
recorded as year only. Hospital admissions were classified according to the 
diagnosis given by the clinical care team at the time. 
For patients who had been transplanted, data were collected regarding; pre-
transplant health, conditioning for transplant, type of transplant, post transplant 
course and any complications. Further information was gathered for time since 
transplant including: growth, number of hospitalisations, infections, and 
medication.  
In addition, for children diagnosed since the registry was developed, information 
was gathered in line with the original registry, covering gender, diagnostic tests 
and mode of inheritance. The proforma used for data collection was amended 
from the original registry proforma in order to be sure of collecting similar 
information. 
For patients that had died, information from the medical records was collected 
regarding progress up until the point of death and cause of death, again using 
the standard proforma. 
Data were entered in to the UK and Ireland CGD database held at Newcastle 
University. All data were checked manually for accuracy and to guard against 
duplication. Data from both the original registry and current update were used 
for analysis of clinical features. 
Number of life years of CGD were calculated for all children managed 
conservatively (date of birth until either date of data abstraction or death) plus 
children managed with HSCT (date of birth until HSCT). Total number of 
transplant years was calculated (date of transplant until either date of data 
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abstraction or death). If children received more than one transplant the later 
date was taken for calculating number of transplant years. 
Number of events were calculated for the commonly occurring infections; 
suppurative adenitis, pneumonia, perianal abscess, liver abscess, osteomyelitis, 
septicaemia, brain abscesses and splenic abscess. Median age at time of 
diagnosis of the infection was calculated. Numbers of X-linked and AR children 
diagnosed with these infections were recorded. Number of serious infections 
after transplant calculated. Number of admissions for other reasons and 
surgical procedures were calculated for pre and post transplant time.
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3.9 Evaluation of Cognitive Function 
3.9.1 History of IQ testing 
Although ability testing for occupations can be traced back to 2200BC in 
China[251], modern assessment of intelligence really began to take off in the 
late 19th century. Francis Galton started to develop tests of sensory 
discrimination that he argued were related to intellect[252]. James McKeen 
Cattell took this further in 1890, describing 10 “mental tests” which included 
measuring the threshold for discerning difference in weights, judging time 
intervals and reaction times[253]. The correlation between these tests and 
intelligence were called in to question when Wissler compared college grades 
with test performance for Columbia University undergraduates in 1901 finding 
no correlation between the two[254]. Charles Spearman introduced the concept 
of “g”, general intelligence, to explain attributes that underpinned a variety of 
different tasks which he tested using sensory experiments with sight, hearing 
and touch[255].  
However, the first true intelligence test, not reliant on sensory tests, was 
developed by Alfred Binet and colleagues in Paris in the early 1900s. The 
French Minister of Public Instruction had commissioned a committee, including 
Binet, to develop a test that would differentiate normal children from those 
requiring special education[256]. These tests were refined over a number of 
years to include an evaluation of “mental age” compared to the normal 
population. In 1912 a German psychologist, William Stern, suggested the idea 
of the “mental quotient” which was gained by dividing the mental age by 
chronological age. The term Intelligence Quotient (IQ) was first used by 
American psychologist, Lewis Terman who multiplied the mental quotient by 
100[251]. He adapted the French Binet-Simon scale and re-named it the 
Stanford-Binet scale. Terman was the first to set the average IQ at 100 with 
average variability of 15. Obviously there are problems with this for adults 
whose chronological age continues well beyond the continued development of 
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their intelligence. For this reason Terman assigned all adults the chronological 
age of 16 years.  
In the 1930s Wechsler started to develop intelligence scales which have since 
been modified but remain some of the most common and well validated forms 
of intelligence assessment. Wechsler devised measures for both children 
(Wechsler Intelligence Scale for Children –WISC) and adults (Wechsler Adult 
Intelligence Scale –WAIS). One of the benefits of the Wechsler scales over the 
previous Stanford-Binet scale was the introduction of a performance scale (for 
example: assembling block patterns, pointing to missing details) which does not 
involve verbally answering questions, so overcoming difficulties with language 
or education. The Wechsler Scales are organised in to four dimensions: verbal 
comprehension, working memory, perceptual organisation and processing 
speed. Within each of these dimensions a number of aspects of cognitive 
function are tested including: logical and abstract thinking, short term memory 
and attention, perception, concentration and attention to detail, motor skills, 
visual motor dexterity and psychomotor speed. Rather than relying on mental 
and chronological age for scoring Wechsler used actual test score compared 
with expected test score for people of the same age and then multiplied by 100. 
The scales provide scores for total IQ, but also verbal and performance IQ. 
Brief intelligence tests have been developed from the longer more in-depth 
tests, for example the Wechsler Abbreviated Scale of Intelligence (WASI) which 
is a standardised short form of the WISC and WAIS. Brief intelligence tests 
were designed mainly as screening tools, when a fast reliable measure of IQ is 
required, but when it is not practical or desirable to undertake a full assessment. 
They can be useful for testing a broad age range of individuals rather than 
being specific to children or adults. They can be administered quickly so are 
often more convenient than the longer, more in-depth tests. They can be useful 
when looking at the effect of cognitive function in association with emotional and 
behavioural problems[257]. However, they are not as accurate as the full scales 
and therefore do have some limitations. They are not recommended for making 
diagnoses of cognitive disorders in individuals without further assessment[258]. 
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3.9.2 Measurement of IQ in CGD patients 
Cognitive function was measured using the Wechsler Abbreviated Scale of 
Intelligence (WASI). Children aged 5 -15 years were eligible for completion of 
the WASI. Children were excluded if they were unable to complete the 
assessment in English or if they had a second diagnosis that would impact on 
their ability to perform the assessment. It was administered by the study PI after 
training from a clinical psychologist. It is composed of four sub-tests, two verbal 
and two performance tests and is a useful short screening tool, taking 
approximately 30 - 45 minutes to administer. Although not as comprehensive as 
the Wechsler Intelligence Scale for Children (WISC), it was more acceptable to 
patients and families as the WISC can take 1.5-2 hours to complete.  
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3.10 Evaluation of psychological health 
Children and their parents were asked to complete questionnaires covering 
different aspects of psychological wellbeing. These were the Strengths and 
Difficulties Questionnaire and the Harter Self Perception Profile.  
3.10.1 Strengths and Difficulties Questionnaire 
The Strengths and Difficulties Questionnaire (SDQ) was designed to measure 
social, emotional and behavioural functioning in children. There are published 
norms for UK children[259]. The SDQ has been used in a wide variety of 
research settings. It is validated as a screening tool for screening for 
psychosocial problems in children with chronic illness. Amongst others, it has 
been used in children with asthma[260], cancer[261] and juvenile idiopathic 
arthritis[262] and to screen for psychological difficulties in paediatric outpatient 
clinics[263]. Parents of children over the age of 5 completed parent report 
questionnaires. Children aged 11 and over completed the self report 
questionnaire.  
The questionnaire provided respondents with statements which they had to 
agree or disagree with. Questions are divided in to five sections regarding 
emotional difficulties, conduct disorders, hyperactivity, peer difficulties and 
prosocial behaviour. Each question can score 0, 1 or 2 points according to how 
much the respondent agrees with the statement. Scores are generated for each 
of the sections. A total score is calculated by summing scores from all sections 
apart from the prosocial score. 
3.10.2 Harter Self Perception Profile for Children 
Harter first developed the perceived competence scale for children in 1979 to 
measure children’s perceived competence in three domains; cognitive, social 
and athletic competence and from this to gain an understanding of global self-
esteem. This has since been refined to include further domains (physical 
appearance and behavioural conduct), so providing a broader, more 
differentiated measure of self-concept compared to single self concept 
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scores[264]. The title was also changed to reflect the assessment of a child’s 
self adequacy as well as competence. In 1988 Harter developed the Self-
Perception Profile for Adolescents, with three additional domains which are of 
relevance to adolescents but not children; job competence, close friendship and 
romantic appeal. 
The Harter Self Perception Profile for Children (SPPC) is a self report 
questionnaire that measures self esteem in children over the age of 8. The child 
self report form was used for 8-12 year olds and the adolescent version for 
those over 12. The questionnaire provides a number of pairs of statements. The 
respondent must decide which of the pair is most applicable and then decides 
whether they strongly agree or partially agree with it. The child questionnaire 
has 36 statements and the adolescent questionnaire has 45 statements, to 
incorporate the additional sections. Each answer has a score of 1 to 4. Mean 
scores for each section were calculated for each patient for scholastic 
competence, social acceptance, athletic competence, physical appearance and 
behavioural conduct. 
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3.11 Evaluation of quality of life 
The Pediatric Quality of Life Inventory 4.0 (PedsQL) is a health related quality of 
life instrument designed for children aged 3 – 18 years[265]. It is designed with 
child self report and parent proxy report scales. There are Generic Core Scales 
that have been validated for use in healthy children and those with medical 
disorders[266]. It is used widely in medical research and has been translated 
into many languages for use across the world. There are published data for 
healthy children in the UK[267]. There are also disease specific scales, for 
asthma, diabetes, cancer and cardiac conditions[265] but none have been 
developed that are appropriate for children with primary immunodeficiency or 
CGD. Therefore, only the Generic Core Scales were used.  
Parents of children aged 3-15 years were provided with parental questionnaires. 
Children aged 5 years and over were provided with age appropriate 
questionnaires. It has been shown that children from 5 years of age can reliably 
report their quality of life using the PedsQL generic core scales[268]. 
The questionnaire is divided into four sections: physical, emotional, social and 
school functioning. Each section contains a number of statements about how 
the respondent feels and what they may have difficulties with. Respondents 
must rate how frequently they experience the difficulty, from never to always, 
which generates a score between 0 and 4. The raw score values of 0 – 4 are 
assigned a scale value between 0 and 100[265]. For each respondent, scores 
were calculated for each of the four domains. This was done by summing each 
individual question scale score and dividing by the number of questions in the 
section. Domain scores were then summed to provide an overall total score and 
also a psychosocial score (emotional, social and school functioning). Maximum 
score for each domain is 100 and the higher the score the better the quality of 
life. 
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3.12 Statistical analysis 
Statistical analysis was performed using IBM SPSS v.17.0. For the clinical data, 
comparisons were made for non-HSCT and post-HSCT serious infections, 
surgical procedures and other admissions. Comparisons of categorical data, for 
example numbers with colitis in the non-HSCT and post-HSCT groups, were 
compared using the Chi-squared test and, when expected numbers were too 
small, the Fishers exact test. Non-normally distributed continuous data were 
analysed using the Mann-Whitney U test. Normally distributed data were 
analysed using the independent sample t-test, paired t-test and one sample t-
tests as appropriate.  
95% Confidence intervals (CI) were calculated for prevalence rates and rates of 
infections/admission, using the formula: 
Upper limit = (1/n)(d + 1.96 x√(d(1-(d/n)))) 
Lower limit = (1/n)(d - 1.96 x√(d(1-(d/n)))) 
Where d= number of events and n=denominator of rate (life years/transplant 
years) 
z-scores were calculated for weight for age (up to age 10 years), height for age 
and BMI for age using WHO growth standards with WHO Anthro software 
version 3.2.2[269], for children aged 0-5 years, and WHO Anthro plus software 
for children aged over 5 years[270]. Comparisons were made for those who had 
not undergone HSCT with those that were at least 2 years post-HSCT, as 
growth has previously been shown to significantly improve in post-HSCT 
children 2 years after transplant[2]. 
z-scores were calculated for spirometry results (FEV1, FVC and FEV1/FVC 
ratio) using Growing Lungs software available from the lungfunction.org website 
which provides z-scores for children from age 3 upwards[271], according to 
recently published data[272]. Mean z-scores were calculated for FEV1, FVC 
and FEV1/FVC ratio. 
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Survival was plotted on a Kaplan-Meier curve.  
PedsQL mean scores were calculated. Mean scores for the non-transplant and 
post-transplant groups were compared with healthy norms using the one 
sample t-test. Mean scores for the non-transplant and post-transplant groups 
were compared using the independent sample t-test. Mean scores for non-
HSCT children were compared to mean scores for UK children with 
inflammatory bowel disease and cancer[267], as markers of severe and life 
threatening disease, using the one sample t-test. Values for cancer and IBD 
were taken from the paper by Upton et al[267]. 
SDQ scores were calculated for each patient for each section plus a total score. 
Mean scores were calculated for non-transplant and post-transplant groups. 
Comparisons were made with UK population norms for the non-transplanted 
and the post-transplant groups using the one sample t-test[259]. Comparisons 
were also made between the non-transplant and post-transplant groups using 
the independent sample t-test. 
Global self-esteem score was calculated along with subscales for: scholastic 
competence, social acceptance, athletic competence, physical appearance and 
behavioural conduct. There are no published norms for Harter results for 
healthy children in the UK. When designed, the questionnaire was validated on 
multiple groups of American children and Harter provides these norms in the 
questionnaire manual. However, there is no one single mean value for healthy 
children. Therefore, comparisons were made with American norms used in work 
published by Radcliffe et al[273] using the one-sample t-test. Comparisons were 
made between those that had and had not undergone HSCT using the 
independent sample t-test. 
WASI full scale, verbal and performance scores were calculated for each 
patient. Mean scores for non-transplant and post-transplant groups were 
calculated for each scale. The value of 100 ± 15 was used as normal. 
Comparisons were made for non-transplant and post-transplant groups with the 
normal population score of 100 using the one sample t-test. Comparisons were 
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made between the mean scores for the non-transplant and post-transplant 
group using the independent sample t-test. The proportion of children with IQ 
below 85 was compared with the expected numbers for the normal population 
(15%) using the exact binomial test. 
A p value of <0.05 was used for significance in all tests. 
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Chapter 4 Clinical outcome in conservatively and curatively 
managed CGD  
4.1 Identification and recruitment 
Interrogation of the existing UK and Ireland CGD Registry identified 30 children 
with a date of birth after 1st June 1994, who were eligible for inclusion in the new 
round of data collection. The last of these were added to the registry in 
September 2004.  
Advertising the study through special interest groups resulted in 20 responses 
from hospitals around the UK. Five consultants identified a total of 16 children 
with CGD.  
Discussion with the Paediatric Immunology team in Newcastle identified 30 
potential participants, 9 of whom were included in the original registry. 
Discussion with the CGD Nurse Specialist at Great Ormond Street identified a 
further 37 children, of whom 12 were in the original registry.  
A total of 78 potential participants were identified(Figure 7). Five children from 
the original registry were excluded for reaching their 16th birthday before they 
could be approached to participate. 73 living children were therefore eligible for 
inclusion, of whom 59(80%) were recruited in to the study. Five children with 
CGD who died before the commencement of the study were also identified.  
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UK children with 
CGD 
83 
Newcastle 
30 patients 
 
GOS 
37 patients 
 
Other sites 
16 patients 
 
7 consented 
0 deceased 
2 over 16 
 
25 consented 
3 deceased 
2 over 16 
 
 
27 consented 
2 deceased 
1 over 16 
 
 
Figure 2: Patient identification and recruitment 
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4.2 Birth prevalence 
30 children were born before 2000. 44 were born between 1st January 2000 - 
31st December 2009. 3 were born after 1st January 2010. Date of birth was not 
available for one deceased patient. 
Observed birth prevalence = 5.6/million live births for 2000-2010 (95% CI 4.05 – 
7.48). 
4.3 Demographics  
Clinical information was abstracted for 62 children, including 4 who were 
deceased prior to the commencement of the study. No notes could be found for 
one deceased patient. 30 children were post-HSCT. Median age at time of data 
collection for the non-HSCT group was 8.95 years (range 0.51 – 16.41 years). 
Median age of the post-HSCT group at the time of data collection was 10.57 
years (range 3.90 – 15.22 years). This was not significantly different (p=0.360). 
57 (92%) children were male. 53 (85%) were X-linked. Of those with autosomal 
recessive (AR) inheritance three had identified p47phox deficiency, one had 
p40phox deficiency and five had no clear identification of the NADPH oxidase 
component involved. 
Date of diagnosis was available for 57 children. 48 (86%) children were 
diagnosed before the age of 5 years. 55 (96%) were diagnosed by the age of 
10. 
Median age at diagnosis for X-linked patients was 1.81 years (range: at birth – 
11.88 years). Median age for AR patients was 4.20 years (range: 0.31 – 14.82 
years). There was a significant difference between median age at diagnosis 
according to mode of inheritance (p=0.017). For those with AR inheritance, the 
median age for diagnosis for males was 5.21 years, compared to 4.06 years for 
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girls (p=0.451). Genetic mutation was documented in the notes of 24 (39%) 
patients. Other than for siblings, the mutations were different in each patient. 
There were a total of 470 life years for CGD (286 life years for non-transplanted 
patients and 184 pre-transplant years for transplanted patients). 
For those that did not consent to join the study; 12 (80%) were male. Median 
age at time of data analysis was 12.5 years (range 0.9-15 years). This was not 
significantly different from those that did consent (p=0.287). 
4.4 Curative treatment 
4.4.1 HSCT 
At the time of data collection 30 (48%) children had under gone a total of 34 
HSCT procedures. 30 were first transplants, four were second transplants. 28 
(93%) were male and 27 (90%) X-linked inheritance. Median age at first 
transplant was 5.25 years (range 0.7 – 15.3 years). Median age at second 
transplant was 8.2 years (range 4.2 – 7.3 years). Time between first and second 
transplant ranged from 0.42 – 6.6 years. Median post-transplant follow up for 
living patients was 3.84 years (range 0.2-9.9 years). Total transplant years were 
124. 
21 transplants were conditioned with busulphan and cyclophosphamide, 8 with 
treosulphan and fludarabine, 3 with busulphan and fludarabine and 1 with 
treosulphan with cyclophosphamide.  
11 transplants were complicated by acute skin Graft versus Host disease 
(GvHD), two also had gut GvHD. 11 had virus reactivation. Two developed 
veno-occlusive disease. Two developed disseminated fungal disease (of which 
1 died). Three transplants were followed by chronic GvHD (2 liver and 1 skin). 
At the time of data collection 12 (40%) children were still receiving some 
prophylactic medication (Cotrimoxazole, Aciclovir, antifungal agents, 
immunoglobulin replacement or penicillin). For those that were over one year 
from transplant, 9/23 (39%) were still receiving some form of prophylaxis. 
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4.4.2 Gene therapy 
Two children underwent rescue gene therapy (without expectation of cure) for 
fungal infection not responding to conventional management. One died, the 
other did not have long term correction of NADPH oxidase activity. He 
recovered from his fungal infection after changing to the newer antifungal drug, 
Posaconazole. 
4.5 Survival 
At commencement of the study five deceased children with CGD were 
identified. Two were post-transplant deaths and three were in non-transplanted 
patients. Information was unavailable for one deceased non-HSCT patient. Two 
further children died after recruitment to the study, one after HSCT and the 
other whilst awaiting a second round of gene therapy.  
Causes of death were varied: respiratory failure secondary to mulch 
pneumonitis, Burkholderia cepacia sepsis and cerebro-vascular event following 
central venous catheter insertion in the non-HSCT children, with fungal 
infection, multi-organ failure following conditioning and severe influenza in the 
post-HSCT children. 
Median age at death in the non-HSCT group was 6.84 years (range 0.92 – 
16.41). Median age at death in the post-HSCT group was 9.18 years (range 
8.55 – 12.58). There was no statistically significant difference in age at death for 
the two groups (p=0.513). All deceased children were male. 4 were x-linked 
inheritance. 
Kaplan Meier plots were generated for the non-HSCT group 
 Figure 8), which demonstrated 90% survival at 15 years of age, and for the 
post-HSCT group   
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Figure 9) which showed 90% survival 9 years after transplant (longest follow 
up). All 3 children in the post-HSCT group who died received their transplant at 
over the age of 5 years. However, survival in those that were transplant younger 
than age 5 was not statistically significantly better when compared to those that 
were transplanted later (p=0.228) 
 
 
 
 Figure 8: Survival in non-HSCT group 
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Figure 9: Survival post-HSCT 
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4.6 Infectious complications of CGD 
There were a total of 138 episodes of serious infection (0.29 per CGD life year, 
95%CI 0.24 – 0.33 infections per life year)(Table 2). Suppurative adenitis was 
the most common infection, with 34 children having at least 1 episode. Median 
number of episodes was one (range 1 – 4). Pneumonia was the second most 
common serious infection, with 27 children having at least one episode. Median 
number of episodes per patient was one (range 1 – 4 episodes). 12 children 
had at least one perianal abscess (median one perianal abscess, range 1 – 8 
episodes). Nine children had a single episode of liver abscess and one had two 
separate episodes. Four children had a single episode of osteomyelitis, one 
child had two episodes (one in the foot and one in the skull). Three children 
each had two episodes of septicaemia and one child had a single episode. 
There were no significant differences between number of children with at least 
one episode of each of the significant infections according to genetic 
inheritance.
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 No of 
patients 
  Total 
no. 
episode
s 
 P 
value 
XL vs 
AR 
 Total 
N=62 
(%) 
XL 
N=53 
(%) 
AR 
N=9 
(%) 
 Median age 
(years)(range) 
 
Suppurative adenitis 
 
34 (55) 31 (58) 3(33) 49 2.20 (0.04-11.6) 0.161 
Pneumonia/empyema 
 
27 (44) 24 (45) 6 (66) 37 4.50 (0.25-13.4) 0.432 
Perianal abscess 
 
12 (20) 12 (23) 0 24 1.63 (0.3-12.6) 0.185 
Liver abscess 
 
10 (16) 10 (19) 0 11 2.38 (0.25-4.2) 0.332 
Osteomyelitis 
 
5 (8) 3 (6) 2 (22) 6 5.82 (0.5-10.3) 0.149 
Septicaemia 
 
4 (6) 4 (7) 0 7 2.67 (0.5-4.1) 0.525 
Brain abscess 
 
2 (3) 2 (4) 0 2 7.13  (3.5-7.18) 0.343 
Splenic abscess 
 
2 (3) 2 (4) 0 2 2.66 (1.4-4.0) 0.729 
Table 2: Infectious complications in children with CGD & those prior to HSCT 
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4.6.1 Causes of infection 
Identifiable causes of serious infection were found in a proportion of cases  
Figure 10). Of the suppurative adenitis episodes, causative organisms were 
found in 15 (31%) episodes. Eleven were S.aureus (one also had 
S.epidermidis). There was one each of Burkholderia cepacia, Haemophilus 
influenzae, histoplasma and Nocardia.  
For the pneumonias, organisms were identified in 19 episodes (51%). Fifteen 
were presumed or proven fungal infection. Seven were presumed. Five were  
A.fumigatus, two A.nidulans and one Scopulariopsis. Three were bacterial and 
one was viral (respiratory syncytial virus). One was multiple 
organisms(Nocardia, aspergillus flavus, aspergillus terreus, mycobacterium 
tuberculosis and Escherichia coli). 
Three liver abscesses had identified organisms, two S. aureus and one 
coagulase negative staphylococcus. Three episodes of osteomyelitis had 
identified organisms, two aspergillus species and one S. aureus. All but one 
episode of septicaemia had bacteria identified: three were Acinetobacter, one 
S.aureus, one streptococcus mitis and one histoplasmosis. Both non-HSCT 
brain abscesses were presumed fungal. 
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Figure 10: Causes of serious infection 
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4.6.2 Post-HSCT serious infections 
One child had two episodes of suppurative adenitis after HSCT, 2.04 and 3.17 
years after transplant. Three children had pneumonia diagnosed after 
transplant, however, 2 were during their transplant admission and 1 a week 
after discharge following HSCT. One child was diagnosed with a fungal brain 
abscess during his transplant admission following his second HSCT. No child 
had a perianal abscess, liver abscess, osteomyelitis, septicaemia or brain 
abscess after discharge following their HSCT. 
   
75 
 
4.7 Inflammatory complications 
Of the 25 (40%) children diagnosed with CGD colitis, 24 were x-linked cases. 
Median age was 3.99 years at diagnosis (range 0.28 -12.24 years). Six received 
an alternative gastroenterology diagnosis before they were diagnosed with CGD 
(Crohn’s disease or cows milk protein allergy).  
23 children underwent a total of 36 colonoscopies, of which 10 were 
documented to have granulomata on histology. Four children diagnosed with 
colitis had no documented colonoscopies. Four children never diagnosed with 
colitis underwent colonoscopy for diarrhoea, poor weight gain and an abnormal 
white cell scan. One child underwent two colonoscopies after HSCT for 
evaluation of GvHD. 
Six children had 11 episodes of admission for gastrointestinal symptoms related 
to colitis; including exacerbation of known colitis (3), bloody diarrhoea (3), poor 
weight gain (3), melaena (1) and 1 planned admission for establishing 
nasogastric feeds.  
18 (75%) children with colitis had documentation of having received 5-
aminosalicylic acid compounds. Eight (33%) also received steroids 
(prednisolone).No child was maintained on steroids without a 5-ASA compound. 
Five (21%) children received azathioprine, all of whom had 5-ASA compounds 
and steroids. One child received infliximab for treatment of colitis prior to HSCT. 
Three children had pyloric outlet obstruction. However, one of these was 
asymptomatic and diagnosis was only made on endoscopy. The two 
symptomatic children received treatment with prednisolone. Five children had 
bladder involvement, four of whom were treated with prednisolone. 
No child was described to have HLH. However, three children received 
immunomodulation for hyperinflammatory states. One received 
methylprednisolone alone, one methylprednisolone and infliximab and one 
methylprednisolone, infliximab, anakinra and pioglitazone.  
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15 (24%) children were documented to have had at least one ophthalmological 
examination. Four children had more than one examination. No non-HSCT child 
had chorio-retinal abnormalities. One child had a post-HSCT examination which 
showed chorioretinitis. 
32 children had a total of 98 chest CTs, 90 (92%) of which were reported as 
abnormal. One was reported as basal changes indicative of fibrosis. One child 
was reported to have small airway disease on two CTs. The other episodes 
were reported as infective (consolidation, cavities or nodules) or were resolving 
infection after an acute episode. Six children had normal CT scans, two children 
having 2 normal CTs each. 
Eight pre-transplant/non-transplant children had at least one spirometry result 
documented (median number of tests was one, range 1-3). Median age at first 
spirometry was 7.79 years (range 5.42 – 11.42 years). Mean FEV1 z-score was 
-0.98 (range -2.97 to 0.96). Mean FVC z-score was -1.00 (range -2.83 to 0.68). 
Mean FEV1/FVC score was 0.03 (range -0.69 to 1.18). Four children had a 
second measure at median age 8.66 years (range 8.17 – 12.83 years). Mean 
FEV1 z-score was -0.88 (range -2.33 to 0.38). Mean FVC z-score was -0.83 
(range -2.31 to 0.37). Mean FEV1/FVC z-score was -0.24 (range -0.37 to -0.06). 
 Four children had post-HSCT measures, only one of whom had a pre-
transplant measure as well as post transplant measure. Two had two measures 
of spirometry. Median age at first measurement was 9.71 years (range 5.67 – 
11.67 years). Mean FEV1 z-score was -0.95 (range -3.83 to 1.53). Mean FVC z-
score was -0.80 (range -3.25 to 1.36). Mean FEV1/FVC z-score was -0.46 
(range -1.44 to 0.26). 
No child had return of colitis or bladder involvement after HSCT.
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4.8 Nutrition 
Recent height and weight measures were available for 30 non-HSCT children 
and 15 children with greater than 2 years post-HSCT follow up. Median age for 
the non-HSCT group was 9.0 years (range 0.83 – 15.25). Median age for the 
post-HSCT group was 10.1 years (range 4.17 – 13.8 years). Median time post-
HSCT was 4.42 years (range 2.25 – 9.00 years). Six (20%) children in the non-
HSCT group had low height for age (z-score less than -2). No child in the post-
HSCT group had low height for age. Five children had low BMI for age in the 
non-HSCT group. No post-HSCT child had low BMI for age. There was a 
statistically significant difference in z-scores for height for age and BMI for 
age(Table 3). 
 Non-HSCT 
N=29 
Post-HSCT 
N=16 
P value of difference 
Mean Height for age 
(SD) 
range 
-1.15  
(1.15) 
-3.42, 1.85 
-0.29  
(0.75) 
-1.62, 1.11 
0.012 
Mean BMI for age 
(SD) 
range 
-0.37 
(1.55) 
-3.26, 2.50 
0.58  
(0.88) 
-0.70, 2.25 
0.012 
Table 3: z scores for height and BMI for age in non-HSCT and post-HSCT children 
 
Weight for age z-scores were calculated for 18 non-HSCT and 7 post-HSCT 
children under the age of 10 years. Mean score for non-HSCT children was -
0.82 (range -3.53 to 0.90). Mean score for the post-HSCT children was -0.24 
(range -1.45 to 1.44). Four children had low weight for age scores (z-score less 
than -2) in the non-HSCT group. No post-HSCT child had low weight for age. 
There was no significant difference in weight for age between non-HSCT and 
post-HSCT children (p=0.141). 
   
78 
 
Pre and post-transplant weights and heights were available for 14 children who 
had undergone HSCT with at least 1 year post-transplant follow up (Figure 11). 
Median time post-HSCT was 4.3 years (range 1.3 – 9.0 years). Seven children 
did not have z-scores for weight for age calculated as they were over 10 at most 
recent measurement. Therefore, weight for age comparisons pre and post 
transplant were not performed. Three (21%) children had height for age z-
scores below -2, deemed low height for age pre-HSCT. One child continued to 
have low height for age post-HSCT.  No child had low BMI for age, pre or post 
HSCT. There was a significant improvement in height for age but no significant 
difference in BMI for age when comparing pre and post transplant(Table 4). 
 Pre-HSCT Post-HSCT P value of difference 
Mean Height for age 
(SD) 
-1.41 (1.03) -0.54 (1.07) 0.011 
Mean BMI for age 
(SD) 
0.20 (0.77) 0.49 (1.04) 0.417 
Table 4: Pre and post-HSCT z scores for height and BMI 
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Figure 11: Height for age z-score pre and post HSCT in 14 patients 
 
Four (6%) children received parenteral nutrition due to poor nutritional status. 
Two (3%) received nasogastric feeds. Three (5%) children received growth 
hormone therapy for poor growth and delayed puberty, all were being 
conservatively managed at the time, although one did go on to receive HSCT. 
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4.9 Other admissions 
There were a total of 52 admissions for other reasons in 30 children (0.11 
admissions per CGD life year, 95%CI 0.08-0.14 admissions per year). Median 
number of admissions was two (range 1 – 4 admissions). Median age at 
admission was 3.5 years (range birth – 12.1 years). 14 episodes were upper or 
lower respiratory tract disorders not treated as pneumonia (tonsillitis, 
pharyngitis, croup, bronchiolitis, cough, otitis media, exacerbation of asthma). 
Eight children had nine episodes of skin or soft tissue infection requiring 
admission and antibiotics. One child had preseptal orbital cellulitis. Two had 
severe Varicella zoster infection requiring intravenous Aciclovir. Three 
admissions were for seizures. Five admissions were with acute diarrhoea (not 
colitis). Two were for CVL infection. One child had three admissions related to 
an expanding mediastinal mass. One admission each for: superior vena cava 
obstruction, Kawasaki’s, Bell’s palsy, ascites of unknown cause and mesenteric 
adenitis. Six admissions were for non-specific viral illness. 
Two neonates were admitted to the neonatal unit at birth for observation due to 
antenatal diagnosis of pericardial effusion. 
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4.9.1 Post-HSCT admissions 
There were a total of 15 admissions in 10 children after discharge following their 
HSCT (0.12 admissions per transplant year, 95%CI 0.06 – 0.18 admissions per 
year). Median age at admission was 6.4 years (range 1.4 – 12.4 years). Median 
time post-HSCT at admission was 0.75 years (range 0.08 – 4.83 years). Ten 
(67%) admissions were within the first year after HSCT.  
Within a year of transplant the admissions were: three with fever, two with viral 
reactivation (Cytomegalovirus and Varicella zoster), two with diarrhoea, one 
with difficult GvHD, one seizure and one urinary tract infection. 
The later admissions were for: two upper respiratory tract infections, headache 
and confusion, a seizure and new onset type 1 insulin dependent diabetes 
mellitus. 
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4.10 Surgery 
37 children underwent a total of 97 surgical procedures in relation to their 
diagnosis of CGD. Median number of surgical procedures per child was 1 
(range 1-12). Median age at surgery was 3.2 years (range 0.28 – 13.6 years). 
This results in a rate of 0.21 surgical procedures per CGD life year (95% CI 
0.17 – 0.24 events per year). 
 29 episodes were incision and drainage (I&D) or aspiration for suppurative 
adenitis. 23 were I&D or aspiration for other collections (soft tissue abscesses, 
thymic abscess, liver abscess, osteomyelitis). Seven episodes were for 
management of perianal abscesses (I&D or laying open of fistula). Nine were 
laparotomies (for liver haemorrhage, partial hepatectomy, partial 
pancreatectomy, splenectomy, splanchnic haematoma, gastric perforation, 
ascites, jejunocolic fistula and removal of packing following previous abdominal 
surgery). Two were cystoscopies for CGD bladder involvement. Eight were 
biopsies of lymph nodes or soft tissue masses. Two children had lymph node 
excision and one had fine needle aspiration. Two had bone marrow aspiration 
and trephine. One child had lobectomy for fungal pneumonia. One child 
required pulmonary artery stenting and a further procedure to dilate the stent. 
One child had a diagnostic nasal space washout related to maxillary 
osteomyelitis. One child had examination under anaesthesia and rectal biopsy 
for constipation and later required anal dilatation. One child needed two 
episodes of debridement for poor wound healing following laparotomy. One 
child required a transjugular portosystemic shunt. Three children required 
central venous access during treatment of infection. One child had 
gastroenterostomy insertion for poor nutritional intake which was later removed. 
Two children had genitourinary procedures which were not directly connected 
with their diagnosis of CGD (hypospadias repair, orchidopexy). 
All children that underwent HSCT had at least one central venous line for the 
procedure. One child required evacuation of intracranial haematoma following 
fungal brain abscess during his transplant admission. 
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Two children underwent surgical procedures after discharge following HSCT. 
One was a roux en y enterostomy for a bile duct stricture. The other was 
excision of a lower lip lesion.  
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4.11 Total admissions pre & post-HSCT 
There were a total of 0.71 events per CGD life year (95%CI 0.69-0.75 events 
per year) and 0.15 events per transplant year (95%CI 0.09-0.21 events per 
year)(Table 5). Children with CGD were 4.7 times more likely to need admission 
to hospital for serious infection, inflammatory complications or surgery when 
compared to post-HSCT children. 
 Pre-HSCT Post-HSCT 
Serious infection 138 0 
Colitis 11 0 
Colonoscopy 36 2 
Other 52 15 
Surgery 97 2 
Total 334 19 
Events per person-year 0.71 0.15 
Table 5: Pre and post-HSCT admissions and events 
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4.12 Prophylaxis 
All children with known CGD received antibiotic prophylaxis with Cotrimoxazole. 
One child died during his presenting acute illness and therefore never received 
prophylaxis. 
 54 (87%) had antifungal prophylaxis with Itraconazole. Six were treated for 
fungal infection at diagnosis and therefore remained on other antifungals rather 
than Itraconazole at the time of data collection. One child never received 
antifungal prophylaxis as he died during his presenting illness. Three children 
were switched to voriconazole prophylaxis due to difficulties with Itraconazole. 
No child received prophylactic interferon gamma. Although 13 did receive it as 
part of treatment for severe infection.
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4.13 Summary 
• 85% of children in the UK and Ireland have X-linked inherited CGD. 
• Median age at diagnosis is significantly younger for X-linked compared to 
AR inherited cases. 
• 48% of children with CGD had undergone HSCT at the time of data 
collection, with 90% survival. 
• Children with CGD had 0.29 serious infections per CGD life year 
(suppurative adenitis and pneumonia were the most common). 
• There were no serious infections after the peri-transplant period. 
• 39% of children with CGD had colitis. 
• Post-HSCT children demonstrated improved height for age compared to 
non-transplant children. 
• Children with CGD had 0.71 episodes of admission or surgery per CGD 
year for all reasons, compared to 0.15 episodes in post-HSCT children. 
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Chapter 5 Quality of life, emotional wellbeing and cognitive function 
in CGD 
5.1 Study of quality of life in CGD 
5.1.1 Parent report scores 
47 parents completed PedsQL questionnaires. Median age of children was 10 
years (range 3-15 years). 44 were parents of male patients. 21 were post-
HSCT. Median age for non-HSCT group was 9 year (range 3-15 years). Median 
age for post-HSCT group was 10 years (range 4-14 years). The post-HSCT 
group were median 3 years post transplant (range 1-9 years). Number of 
children with colitis in the two groups did not differ significantly, 10 in the non-
HSCT group and 8 in the post-HSCT group respectively (p=0.807). 8 children in 
the non-HSCT group had suffered presumed or proven fungal infection 
(pneumonia, brain abscess or osteomyelitis) compared to only 2 in the post-
HSCT group (p=0.150).  
Scores for the non-HSCT group were significantly lower across all domains 
when compared to population norms(Table 6). Scores for the post-HSCT group 
were not significantly different from population norms. Scores for the post-HSCT 
group were significantly higher than those for the non-HSCT group in all 
domains.
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 UK norms No HSCT 
N=26 
P value: 
norms vs 
no HSCT 
Post 
HSCT 
N=21 
P value: 
norms 
vs post-
HSCT 
P value: 
no HSCT 
vs post 
HSCT 
Domain Mean (SD) Mean (SD)  Mean (SD)   
Total 84.6 (11.2) 65.31 
(20.43) 
<0.001 81.93 
(18.74) 
0.521 0.006 
Psychosocial 82.2 (12.7) 66.74 
(19.25) 
<0.001 81.17 
(16.80) 
0.782 0.010 
Physical 89.1 (12.3) 60.35 
(25.74) 
<0.001 85.27 
(25.27) 
0.495 0.002 
Emotional 78.3  
(15.5) 
65.53 
(20.08) 
0.003 78.81 
(18.57) 
0.901 0.024 
Social 86.8 (15.4) 71.88 
(21.48) 
0.002 88.33 
(17.42) 
0.691 0.007 
School 81.5 (16.1) 55.88 
(21.92) 
<0.001 79.13 
(22.99) 
0.641 0.001 
Table 6: Parent report PedsQL mean scores 
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*p=<0.05, **p=<0.01 
 
Compared to UK children with cancer and inflammatory bowel disease, children 
with CGD scored significantly worse for physical, social and school 
domains(Figure 12). 
 
Figure 12: Parent report scores for non-transplanted CGD patients compared to other diseases 
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5.1.2 Self report scores 
35 children (33 males) completed self-report PedsQL questionnaires. 18 were 
post-HSCT. Median age was 10 years (range 5-15 years). Median age for both 
groups (non-HSCT and post-HSCT) was 10 years. The post-HSCT group were 
median 4 years post transplant (range 1-9 years). 
Non-HSCT children reported significantly lower scores than population norms in 
all except the emotional domain(Table 7). Post-HSCT children had scores not 
significantly different from normal in all domains. There were significant 
differences in scores for the individual domains (physical, emotional, social and 
school) but not the combined scores when comparing non-HSCT and post-
HSCT groups. 
 UK norms No HSCT 
N=17 
P value: 
norms 
vs no 
HSCT 
Post HSCT 
N=17 
P value: 
norms 
vs post-
HSCT 
P value: 
no HSCT 
vs post 
HSCT 
Domain Mean (SD) Mean (SD)  Mean (SD)   
Total 83.9 (11.8) 75.39 
(12.99) 
0.016 81.79 (20.22) 0.664 0.276 
Psychosocial 81.8 (13.2) 74.61 
(13.27) 
0.040 80.28 (19.10) 0.739 0.318 
Physical 88.5 (11.6) 69.68 
(17.69) 
<0.001 89.93 (17.20) 0.729 0.002 
Emotional 78.5 (17.9) 72.64 
(14.37) 
0.113 85.83 (16.20) 0.072 0.016 
Social 87.7 (16.5) 73.53 
(17.12) 
0.004 89.71 (19.16) 0.672 0.014 
School 78.9 (15.9) 64.12 
(15.64) 
0.001 79.12 (18.73) 0.962 0.016 
Table 7: Self reported PedsQL mean scores 
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Children with CGD had scores similar to those reported by children with IBD 
and cancer in all except the social domain, where the CGD score was 
significantly lower than that for IBD(Figure 13). 
 
*p=<0.05 
Figure 13: Self report scores for non-transplanted CGD patients compared to other diseases 
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5.2 Study of emotional and behavioural difficulties in CGD 
5.2.1 Parent report scores 
42 parents completed SDQs. 39 were parents of male patients. Median age of 
all children was 10 years (range 3-15 years). 19 (45%) were post-HSCT. 
Median age of non-HSCT group was 9 years. Median age of post-HSCT group 
was 10 years. The post-HSCT group were median 4 years post transplant 
(range 1 -9 years). 
When compared to population norms for males the non-HSCT group had 
significantly higher total and emotional scores(Table 8). The post-HSCT group 
mean scores were not significantly different from population norms. The post-
HSCT total score was significantly lower than the non-HSCT group. The post-
HSCT score for hyperactivity was significantly lower than the score for the non-
HSCT group. 
 UK 
norms for 
males 
No HSCT 
N=23 
P value: 
normal vs 
no HSCT 
Post 
HSCT 
N=19 
P value: 
Normal 
vs post-
HSCT 
P value: 
no HSCT 
vs post 
HSCT 
Domain Mean 
(SD) 
Mean 
(SD) 
 Mean 
(SD) 
  
Total 9.1 (6.0) 12.09 
(6.19) 
0.030 7.74 
(5.70) 
0.311 0.024 
Emotional 1.8 (2.0) 2.83 
(2.10) 
0.029 1.74 
(2.05) 
0.895 0.099 
Conduct 1.7 (1.8) 2.00 
(1.41) 
0.320 1.63 
(1.86) 
0.875 0.471 
Hyperactivity 4.0 (2.7) 5.04 
(2.44) 
0.052 3.16 
(2.28) 
0.123 0.014 
Peer 1.5 (1.7) 2.22 
(1.95) 
0.092 1.21 
(1.40) 
0.379 0.067 
Prosocial 8.3 (1.6) 8.3 (1.40) 0.988 8.05 
(1.58) 
0.504 0.587 
Table 8: Parent report SDQ scores for non-HSCT and post-HSCT groups 
 
   
93 
 
5.2.2 Self-report scores 
19 children (all male) completed self-report SDQs. Median age was 13 years 
(range 10-15). 10(53%) were post-HSCT. Median age of the non-HSCT group 
was 14 years. Median age of the post-HSCT group was 13 years. The post-
HSCT group were median 4.5 years post transplant (range 1-9 years). 
There were no significant differences between mean scores for the non-HSCT 
group and population norms(Table 9). The mean conduct score was 
significantly lower in the post-HSCT group than the population norm. There 
were no significant differences between the non-HSCT and post-HSCT groups. 
 UK norms 
for males 
No HSCT 
N=9 
P value: 
normal vs 
no HSCT 
Post 
HSCT 
N=10 
P value: 
normal 
vs post-
HSCT 
P value: no 
HSCT vs 
post HSCT 
Domain Mean (SD) Mean (SD)  Mean (SD)   
Total 10.5 (5.1) 10.56(4.77) 0.973 7.70 (5.49) 0.139 0.244 
Emotional 2.6 (1.9) 2.00 (2.18) 0.433 2.00 (1.83) 0.326 1.000 
Conduct 2.4 (1.7) 2.00 (1.73) 0.508 1.30 (1.25) 0.021 0.323 
Hyperactivity 3.9 (2.2) 4.33 (1.94) 0.521 2.50 (2.76) 0.143 0.116 
Peer 1.6 (1.4) 2.22 (1.97) 0.375 1.90 (1.73) 0.597 0.710 
Prosocial 7.5 (1.7) 7.11 (1.61) 0.491 7.50 (1.90) 0.936 1.000 
Table 9: Self-reported mean SDQ scores 
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5.3 Study of self-esteem in CGD 
25 children (24 males) completed the Harter questionnaires. Median age was 
12 years (range 8-15 years). 13 children were post-HSCT. Median age for the 
non-HSCT group was 14, whereas median age for the post-HSCT group was 
10 (this was not statistically significant p=0.085). The post-HSCT group were 
median of 4 years post-HSCT (range 1-9 years). 
The non-HSCT group had a significantly lower score for athletic competence 
when compared to published norms(Table 10). The post-HSCT group had 
significantly better scores for global self-esteem along with conduct compared 
to norms.  
 
 norms Non-HSCT 
N=12 
P value: 
norms vs 
non-HSCT 
Post-
HSCT 
N=13 
P value: 
norms vs 
post-
HSCT 
P value: 
non-HSCT 
vs post-
HSCT 
Global 3.02 
(0.67) 
3.19 (0.52) 0.266 3.49 (0.68) 0.028 0.239 
Athletic 3.02 
(0.73) 
2.15 (0.57) <0.001 2.76 (0.91) 0.333 0.059 
Conduct 2.80 
(0.55) 
3.09 (0.58) 0.108 3.38 (0.75) 0.017 0.294 
Appearance 2.79 
(0.71) 
3.06 (0.61) 0.157 3.16 (0.61) 0.052 0.951 
Scholastic 2.85 
(0.67) 
3.00 (0.60) 0.406 3.02 (0.98) 0.542 0.856 
Social 2.94 
(0.65) 
2.96 (0.65) 0.901 3.29 (0.65) 0.087 0.232 
Table 10: Mean Harter self-esteem scores for non-HSCT and post-HSCT groups 
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5.4 Study of cognitive function in CGD 
23 children (all male, 22 X-linked) completed the WASI. Median age for all 
children was 10 years (range 7-15 years). One child was excluded due to a 
diagnosis of autistic spectrum disorder that would impact on ability to perform 
the test. One child, with intracranial fungal infection and sensorineural hearing 
impairment was unable to concentrate to complete the test and therefore did not 
receive a score. 10 children completed the WASI post-HSCT. Median age for 
both non-HSCT and post-HSCT groups was 10 years. The post-HSCT group 
was median 3.5 years post transplant (range 1-9 years). 
There were no significant differences when comparing non-HSCT and post-
HSCT groups with the population mean score 100 for verbal, performance or 
total IQ. There were no significant differences in mean score for verbal, 
performance or total IQ when comparing non-HSCT and post-HSCT groups 
(Table 11). 
Four children (17%) had IQ <85 (2 post-HSCT). This was not significantly 
different from the expected proportion of children in a normal population 
(p=0.46). No children had IQ<70. 
 
 Non-HSCT 
Mean (SD) 
N=13 
Post-HSCT 
Mean (SD) 
N=10 
P value: 
Non-HSCT vs post-
HSCT  
Verbal 102.08 (21.16) 96.50 (15.55) 0.492 
Performance 100.00 (10.34) 103.30 (16.37) 0.560 
Total 101.00 (16.69) 100.40 (17.84) 0.935 
Table 11: Mean IQ scores for non-HSCT and post-HSCT groups 
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5.5 Summary 
• Parents and children with CGD reported poor quality of life compared to 
healthy norms. 
• Parents and children that had undergone HSCT for CGD reported quality 
of life that was normal. 
• Parents of children with CGD reported increased risk of emotional 
difficulties when compared to the healthy population. 
• Children that had undergone HSCT for CGD had higher global self-
esteem than those managed conservatively. 
• Children with CGD reported lower self-esteem in terms of their athletic 
competence. 
• Children with CGD and those transplanted for it had normal IQ. 
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Chapter 6 Discussion 
6.1 Discussion of clinical outcome studies 
6.1.1 Identification and recruitment 
This study aimed to survey the clinical outcome in the UK and Ireland paediatric 
CGD cohort. Due to the cooperation of the supra-regional centres, the CGD 
Nurse Specialist and wide advertising of the study it was possible to identify 
virtually all children with CGD. It is unlikely that any children known to have 
CGD were missed and not given the opportunity to join the study. It is, however, 
possible that further children are yet to be diagnosed, especially those born in 
recent years. It is also unlikely that any deceased children with a known 
diagnosis of CGD were missed. However, death certificates were not reviewed 
to identify any further children who may have had CGD without confirmation. 
This study managed to recruit 80% of the known children living with CGD. This 
is a large proportion of the UK and Ireland paediatric CGD cohort and is similar 
to the percentage of both adults and children, recruited by Jones et al when the 
UK and Ireland CGD registry was set up[1]. Those that did not consent to 
involvement were mainly male, as would be expected for CGD, and were 
spread across the paediatric age range. Median age was not significantly 
different from the children that did join the study. However, no other information 
was available about them to evaluate whether they differed significantly from 
those that did join the study, in terms of their clinical condition. Therefore, it is 
not possible to be certain that no bias has been introduced in to the sample. 
Because of the high level of recruitment, the results of this study should be 
considered representative of the UK and Ireland paediatric CGD population. 
6.1.2 Birth prevalence 
The observed birth prevalence for the 2000-2010 was 5.6/million. This is lower 
than that described by Jones at el for 1990-1999 (7.5/million), which was in turn 
lower than the prevalence for the decade 1980-1989 (8.5/million)[1]. However, 
the confidence intervals are wide, with the upper limit closer to Jones et al’s 
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calculation.  It is also likely that the calculated prevalence is an under estimate 
as some children, particularly those born later in the decade, may yet to be 
diagnosed. It is, therefore, most likely that the prevalence rate is relatively 
stable. There is no reason to expect a dramatic change. For example, pre-
implantation diagnosis is not yet widely available to result in a reduction in 
numbers of births of children with CGD.  
6.1.3 Demographics  
As expected the majority of patients were male and X-linked inheritance. The 
proportion of X-linked cases (83%) is similar to that described by Jones et al 
previously for the UK[1]. Similar to previously reported in UK, Italian and 
European registries the median age at diagnosis was lower for X-linked cases 
compared to AR cases[1, 77, 103]. The median age for diagnosis in both X-
linked and AR cases was lower in this study than the published registries but 
this is a result of it being a paediatric study, which does not include any late 
adult diagnoses. It is, therefore, not possible to determine whether we are 
getting better at recognising and diagnosing CGD in early life. It has been 
argued that the later diagnosis in AR inherited cases has previously been 
because clinicians do not think about CGD in girls. However, in this study the 
median age at diagnosis for AR girls was not different to AR boys. This 
suggests that in the UK clinicians do consider the diagnosis of CGD in a girl if 
she presents with typical features. Historically, there has been lots of discussion 
about whether AR cases are less severe and, therefore, present later. However, 
as has more recently been highlighted, genetic mutation and resultant residual 
NADPH oxidase activity are associated with disease severity[79]. This study, 
although attempting to document known genetic mutations, did not consider 
residual NADPH oxidase activity and cannot, therefore, contribute further to this 
area.  
Interestingly, within the AR inheritance group this study includes one child with 
p40phox deficiency. This has only been described once before, in a patient with 
colitis[85]. Whereas, the child in this study presented with significant infections. 
This is a new description of presentation of p40phox deficiency. 
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6.1.4 Curative treatment 
Approximately half of the children in the UK and Ireland had undergone HSCT 
at the time of data collection. Since data analysis was undertaken, further 
children have also undergone HSCT and more are awaiting it. This is a 
significant change from historical practice. This study includes a larger group of 
transplanted children than any published case series. Gene therapy for CGD 
remains experimental. This study has shown it has been used in the UK when 
no suitable donor for HSCT has been available. In one case in this study it 
appeared to have minimal benefit and in the other it did result in improvement in 
clinical condition. 
For the post-transplant children, 60% were off all prophylactic medication by 
one year after transplant. However, it must be noted that the two main centres 
for primary immunodeficiency HSCT have different policies. One aims to stop all 
medication, whilst the other continues life-long pneumococcal prophylaxis. 
Therefore, with current policy it will not be possible to achieve 100% of children 
off all medication. This is, perhaps, an issue for discussion by the two centres to 
see if consensus can be reached. However, this is a positive point for families 
considering HSCT. Without HSCT it is absolutely necessary to remain on 
prophylaxis life long, whereas, following HSCT there is a good chance they will 
not need medication. This is particularly attractive for teenagers who are known 
for their poor compliance in other diseases such as diabetes, inflammatory 
bowel disease, and even in life threatening states such as after solid organ 
transplant[274-276].  
6.1.5 Infectious complications 
Overall, suppurative adenitis was the most common infection. Whereas, it was 
only second most common behind pneumonia in the Jones et al paper and the 
Italian registry[1, 103]. Comparison with the European Registry is slightly more 
complicated as they divide episodes by site of disease rather than infectious 
and non-infectious complications. Lymphadenitis appears the second most 
common infection behind pneumonia and lung abscess together[77].  
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The difference between published work and this study may reflect the fact that it 
is purely a review of paediatric cases. In Jones et al’s paper median age for 
pneumonia was 10.2 (range 0.2 – 56.9 years), compared to median age 2 years 
(range 0.2 – 28.8 years) for suppurative adenitis, reflecting the fact that 
suppurative adenitis is a disease of earlier childhood and pneumonia occurs 
later[1]. 
Liver abscesses appeared to be less common than in the original UK registry, 
which reported 79 episodes in 27 (29%) patients[1]. The European registry also 
reported liver abscesses in 32% patients[77]. Whereas, the current study shows 
only 16% of cases had a liver abscess. This is similar to the frequency reported 
in the Italian Registry[103]. Again, this apparent reduced frequency may be due 
to only collecting data on children. According to Jones et al the median age for 
liver abscess was 14.3 years, with a maximum age of 38 years. Therefore some 
of the children presented here may go on to develop liver abscesses as they get 
older. 
S.aureus was the most common bacteria causing infection, as would be 
expected. There were, however, some more unusual organisms identified, for 
example, H.influenzae, Acinetobacter and Histoplasma. The histoplasmosis 
occurred in a child from the Republic of Ireland. Although histoplasmosis is 
unusual in this geographic region, there are cases reported in Europe[277]. 
History of travel to an endemic area was not recorded in this child. It is 
reassuring to know the spectrum of bacteria causing infection in CGD has not 
changed significantly. We can be reassured that our empiric antibiotics are still 
likely to cover the majority of organisms. 
As expected, fungal infections were common. Of those that were proven, A. 
fumigatus remained the most common pathogen. However, many were 
presumed rather than proven infection. This shows that it remains difficult to 
identify fungus. It may be that some of these presumed fungal pneumonias 
were, in fact, not infection at all but rather an inflammatory process as part of 
the CGD phenotype. However, it is unlikely any clinician would feel confident 
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withholding antifungal treatment from a child with a known predisposition to 
fungal infection in the face of clinical suspicion. Because the treating clinician’s 
diagnosis was taken as the diagnosis for each episode, rather than applying 
hindsight to amend the diagnosis at time of data collection, it is not possible to 
determine how many were infectious or inflammatory episodes. 
Serious infections were only seen in non-HSCT patients and HSCT patients 
prior to the time of transplant. The serious infections that occurred in the post-
transplant group (all around the time of transplant) were likely to have been 
present pre-HSCT and unmasked by conditioning with chemotherapy.  
Other, less serious infections were relatively common in children with CGD, 
particularly upper respiratory tract and skin or soft tissue infections. It is difficult 
to draw conclusions about the rate of admission for upper respiratory tract 
infection compared to other children, as it is difficult to establish what would be 
expected from a normal, immunocompetent population. There are also many 
variations from season to season and year to year for the population in terms of 
respiratory infections, these include the seasonal peaks for respiratory syncytial 
virus[278], and in recent years, pandemic influenza[279] and the current  
outbreak of pertussis[280]. It is likely that children with CGD present to hospital 
for evaluation more frequently as parents are told to seek medical help if 
concerned about fever or respiratory infection in order not to miss a significant 
and potentially life threatening infection.  
Of the less serious infections in the post-HSCT, two thirds were within the first 
year after transplant and were transplant related. The causes for admission at 
greater than a year after transplant were varied and not specifically transplant 
related. This suggests that by a year after transplant the children are relatively 
well. However, it is not possible to determine whether the rate of admission is 
higher than the background rate for healthy children for all causes. 
No children were seen with disseminated BCG. Although the UK policy is to 
only vaccinate children deemed to be at high risk, the Irish policy is to vaccinate 
all children at birth. Vaccination records were not recorded for the children in 
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this study so it is not possible to determine how many, if any had received BCG. 
One child did have mycobacterium tuberculosis identified on broncho-alveolar 
lavage, at initial presentation, as part of a mixed group of organisms causing 
pneumonia. However, this child had travelled to a high incidence country prior 
to presentation.  
6.1.6 Inflammatory complications 
40% children developed CGD colitis. This is similar to the findings of Jones et 
al, with 37% having colitis[1]. This is much higher than the frequency described 
in the Italian Registry 6/47 (13%)[103]. It is also much higher than the figures in 
the European Registry. However, this divides gastrointestinal manifestations in 
to colitis and diarrhoea separately without clarifying the difference and also 
counts gastroenteritis as distinct from these. Van den Berg et al report colitis in 
only 9% of patients and diarrhoea in 13%[77]. The reasons for these differences 
are unclear and may relate to definition and detail of data collection. It may be 
that in the UK we are actively asking our patients about and recording their 
gastrointestinal symptoms. This information was also actively sought during the 
data abstraction process. Given that the European registries relied on reports 
from  labs and immunology specialists it may be they did not have information 
regarding gastrointestinal symptoms available to them. 
 It seems the most commonly used agents for management of CGD colitis are 
5-ASA compounds. Steroids were also required in one third of those with colitis, 
suggesting that 5-ASA compounds alone do not  keep the colitis in remission, 
as has previously been suggested by Marks et al[131]. Azathioprine was also 
used in a fifth of children. Detailed data were not collected on response to 
treatment so it is not possible to draw further conclusions about the 
effectiveness of any particular therapy for CGD colitis. The need for multiple 
agents again suggests CGD colitis remains difficult to manage. 
This study is the first to demonstrate the difference in height for age between 
non-HSCT and post-HSCT groups. The non-HSCT group has significantly lower 
height for age when compared to the post-HSCT group. However, the mean z-
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score for the non-HSCT group is still within 2 standard deviations of expected 
and therefore not counted as low for age. It also demonstrates improvement in 
height for age z-scores pre and post transplant in a small group of patients. 
Soncini et al showed good catch up growth 2 years after HSCT[2].  This study 
further adds to this, showing that there is significant improvement in height after 
1 year of follow up post-HSCT when compared to pre-transplant heights. It 
would have been interesting to further evaluate weight for age comparisons in a 
larger group of children as one would expect improvements post-HSCT with 
resolution of colitis symptoms. Only small numbers were available in this study 
with documented weights, so results of any such comparison would be very 
limited in their usefulness. The lack of recorded weights was surprising, and not 
explainable, given that this is normal practice in most paediatric clinics.  
This study did not evaluate pulmonary inflammatory complications in detail.  
Although many children had chest CT these were mainly for infection, with only 
two children having any evidence of chronic lung disease. Only a small number 
of children had spirometry results, which was surprising, given previously 
identified concerns about chronic lung disease. Mean z-scores for FEV1, FVC 
and FEV1/FVC ratio were not outside the normal range but on such small 
numbers it is very difficult to draw any conclusions. With such small numbers, 
evaluating change over time or pre/post-HSCT has little meaning.  It is likely 
that adults are more at risk of chronic lung disease and the paediatric 
population is the wrong cohort to evaluate.  
6.1.7 Prophylaxis 
It is reassuring that all children received appropriate prophylaxis with 
Cotrimoxazole. This is better than reported by Jones et al where not all patients 
were receiving Cotrimoxazole which is now standard practice for CGD[1]. In the 
original registry 93% patients were receiving Itraconazole. It is slightly difficult to 
compare with the current study as Jones et al have not documented whether 
the reason some patients were not on prophylaxis was because they were 
being treated for fungal infection, as was the case in the current study. It is 
reassuring that all children diagnosed with CGD, without evidence of fungal 
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infection, were receiving antifungal prophylaxis. A small number were on 
voriconazole prophylaxis due to difficulties with Itraconazole. Voriconazole is 
often used as first line antifungal treatment in CGD, therefore, there would be 
concerns about potential resistance if widely used prophylactically. However, it 
is not unreasonable to use in those cases where Itraconazole cannot be 
tolerated as it has a good spectrum of activity against fungi of concern in CGD, 
namely aspergillus species. No child in this study received prophylactic 
interferon gamma. Whereas, a recent American series by Martinez et al 
regarding HSCT in CGD states that all children were on interferon gamma prior 
to transplant.[174] This demonstrates the continued division between Europe 
and America on this issue.  
6.1.8 Survival 
Three children in both the non-HSCT and post-HSCT groups died.  90% of the 
non-transplanted children were still alive at age 15 years. This is slightly better 
than survival reported by Jones et al, where survival for males at age 15 years 
was approximately 80% and survival for females was closer to 75%[1]. 
Pneumonia and septicaemia were common causes of death in the original 
registry. These were also the causes of two out of the three deaths in the non-
HSCT group in the current data. One death was a child who had not previously 
been diagnosed with CGD so was not taking prophylaxis. One was an 
unexpected event following surgery, so, although he would not have been 
having surgery if he did not have CGD, it was not a death directly due to 
infection. This suggests we may have become better at managing children with 
recognised CGD so that they are now rarely dying in childhood. It is not 
possible to draw any other conclusions about long term survival as data 
collection stopped at age 16 in this study. Further analysis of adult deaths would 
be important to assess how much the survival curve has changed and whether 
long term survival has really significantly improved. 
When analysed by age the post-HSCT group have 80% cumulative survival at 
age 15 years. However, this is a misleading view of transplant survival and 
reflects the age at which the children were transplanted, along with the age at 
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which the deaths occurred. A far better way to understand transplant survival is 
to look at years of survival after transplant. 
Long-term post-HSCT survival is good, deaths all occurred relatively early after 
transplant (the latest at 2 years). All children that died received their transplant 
later in childhood but the difference in survival was not statistically significant 
when compared to those that received their transplant before the age of five. 
This is something that has historically been identified in HSCT for Wiskott-
Aldrich Syndrome[281] but was not evident in more recent work[282].  It is 
reassuring that older children in this study appear to do well after transplant, 
however, the lack of significance may reflect the small numbers involved. The 
deaths all occurred within two years of transplant and survival has remained 
constant since then. It is the same survival rate as demonstrated by Soncini et 
al, which is one of the largest groups of CGD transplants described in recent 
years. However, this study does include some children who will have also been 
included in that paper[2]. Survival in this study is better than the post-HSCT 
survival quoted for Seger et al’s historical European series of 27 cases (85% 
survival)[172] and in the European registry which was only 80%[77]. However, 
no details are provided about the cases in the study by van den Berg et al. The 
data were collected from 2000-2003 so they may have been early CGD 
transplants. Better survival in the current study may reflect overall improvement 
in HSCT survival for primary immunodeficiency.  Gennery et al showed that 
survival following HSCT for primary immunodeficiency improved after 1995 
compared to previously[283]. The recent case series by Martinez et al 
demonstrated 100% survival which provides hope for the future[174]. The 
American children were slightly younger than the children in this study, with a 
median age of 3.8 years. They had a similar infection history, with bacterial and 
fungal infections and two had colitis. They were all conditioned with a 
Busulphan based regime and had good neutrophil engraftment, although four 
did have grade I GvHD. Although, it is unlikely we will ever achieve 100% 
survival across all CGD transplants, in all circumstances, it does provide 
reassurance that HSCT can be a safe and effective procedure in children with 
CGD. 
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6.1.9 Strengths of the study 
CGD is unusual in terms of primary immunodeficiencies as there are two 
distinct cohorts of similar ages, pre and post-HSCT. Many other primary 
immunodeficiencies are either treated early in life (e.g. severe combined 
immunodeficiency) or are managed with prophylaxis (e.g. antibody 
deficiencies). This is the first study to compare the outcome of these two 
different groups in CGD. Due to the cooperation of specialists across the UK 
and Ireland we can be confident we identified all the known paediatric patients. 
This is different from other studies which have relied on tertiary specialists to 
report cases. Although there would be an expectation that all children with such 
a rare condition are managed at centres of excellence a number of cases 
scattered around the UK, without input from the specialist centres, were 
identified. We had good levels of recruitment, particularly from face to face 
recruitment. The data collection was also very detailed and because it was done 
by a single researcher it was recorded consistently. By not relying on local 
clinicians to provide information it was possible to obtain detail that may 
otherwise not have been completed. Therefore, the findings of this study should 
be representative of the UK cohort of children with CGD, or post-HSCT for it.  
6.1.10 Limitations of the study 
One of the key limitations to the study is the small numbers involved. However, 
this is a result of the rarity of CGD and is the largest such study that can take 
place in the UK. The other key limitation is that it was a retrospective study. 
Ideally a prospective study would be performed looking at both clinical and 
quality of life aspects over time in the non-transplant and post-transplant 
groups. However, due to rarity of the disease and the fact that many are now 
going on to have earlier HSCT, it would not be possible to generate two groups 
of children to compare over time within the UK. 
There were also some other specific difficulties. Recruitment was very good for 
face to face contact but less successful for those approached by post. The 
postal approach was only used when it was not possible to set up face to face 
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meetings at clinic appointments, due to time constraints, clashes of clinics at 
different sites or families not attending for booked appointments. Clinical 
information was available for 62 of the children. Notes could not be found on 
one deceased child. Some of the records that were available were limited, for 
example, in some cases only the second volume could be found. Some records 
have been transferred to electronic format and the quality of these is variable. It 
is therefore possible that some information was missed and rates of infection 
etc are an under estimate of true values. At commencement of the study it was 
planned to review medical records at all centres a patient was seen at. 
However, this was found to be impractical due to time constraints and difficulty 
obtaining access to records. Therefore, only records from major centres 
significantly involved in the care of the patient were reviewed. Accuracy of data, 
therefore, relies on clinicians at these centres recording any events that may 
have happened elsewhere. For example, some minor admissions may be 
missed if patients were seen at their local hospital. Despite this, the data are 
probably more accurate than in those studies that relied on specialist centre 
clinicians to complete a proforma. With busy schedules they would have limited 
time to complete the information and may not have had opportunity to review 
old notes.  
There were particular issues for data collection from patients originating from 
the Republic of Ireland. The original intention was to travel to Ireland to collect 
data. However, due to the ethics process required and the set up of the health 
service with individual private hospitals, this was not possible. Irish patients 
were therefore recruited on their visits to the UK and data were only gathered 
from their UK medical records. These records did included copies of letters from 
their clinic appointments in Ireland which were attended by the visiting 
consultant immunologist from the UK. All other correspondence from Ireland 
was also reviewed to check for details of admission, infection surgery etc. 
However, it is possible some details were missed for the small number of 
patients from Ireland as their local records could not be directly accessed. 
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Due to the way data were collected and entered in to the database by one 
individual (the author) there was the possibility of omissions or errors in data 
entry. Data were manually checked when entered to prevent duplication and 
new data were checked against that already held within the registry for existing 
patients but it was possible some errors could have been introduced. This could 
have been addressed by arranging for an independent person to audit a 
percentage of the entries to check for accuracy. However, this was an individual 
research project and there was no one available to do this. If there are 
inaccuracies it is likely these take the form of omissions of detail regarding 
admissions, infections etc. Therefore, again the rates may be an underestimate 
of the true infection, admission and surgery rates. 
This study did not endeavour to address the issue of genetics and disease 
severity. Although genetic mutations were documented in some cases, they 
were not available for all and details of residual NADPH oxidase activity were 
not recorded therefore no conclusions can be drawn about this. The CGD 
registry also does not contain detail about ethnic origin, which would be an 
important factor to address. This may have implications for inheritance, genetic 
mutations and residual NADPH oxidase activity. 
This study is not able to make any conclusions about long term morbidity and 
survival in patients with CGD as it only includes paediatric data. To really 
evaluate what has happened over the last decade it would be important to look 
at adult survival as well. 
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6.2 Discussion of quality of life, emotional wellbeing and cognitive 
function studies 
6.2.1 Quality of life 
This study demonstrates that children with CGD have poor quality of life when 
compared to the normal population. This may seem obvious, but as previously 
discussed clinician and patient perspectives on quality of life do not correlate 
well and it has never before been measured in CGD[194]. It is therefore 
important to measure quality of life directly from the patient and family 
perspective. This is the first study to do so in CGD. According to the parents, 
quality of life in children with CGD appears to be similar to those with 
inflammatory bowel disease and cancer. In fact, it is rated as worse for specific 
areas of quality of life (physical, social and school) when compared to IBD. 
Parents also reported more impact on physical quality of life for CGD when 
compared to cancer. This demonstrates how significant an impact CGD has on 
a child. 
The children reported significantly poorer quality of life compared to healthy 
children in most domains. Interestingly, however, they did not report worse 
emotional quality of life compared to healthy children, whereas their parents did. 
It is well know that children report better quality of life for themselves than their 
parents often do. This may be because they do not know any different, 
whereas, their parents will be comparing to what they expect from a “normal” 
child. It may be that these children feel they have adjusted to their diagnosis. 
Most interesting is the fact that post-HSCT children have quality of life that is 
normal when compared to healthy children. This is the first study to 
demonstrate this difference between non-HSCT and post-HSCT children with 
primary immunodeficiency and has been demonstrated in both parents and the 
children themselves. Parental scores were also significantly better for post-
HSCT children compared to non-HSCT children across all domains. 
When child self report non-HSCT and post-HSCT groups were compared there 
were no statistically significant differences in total and psychosocial score. This 
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lack of significance may be related to the small sample size and may also be 
because the non-HSCT group started from a higher point (although still 
significantly below normal). This would, again, be explained by children 
reporting better quality of life than parents. 
This study cannot determine causality for improved quality of life post-HSCT as 
it is a cross-sectional survey carried out at one time point. It also does not 
evaluate whether the clinical features of the two groups could result in 
differences. However, it would be difficult to determine which features of the 
disease may impact on perception of quality of life. As already discussed 
clinician perception of quality of life differs from the patient perspective and 
therefore making decisions about what is “severe” disease and what is “mild” 
may have no bearing on what the patient feels. In other conditions, for example, 
asthma and juvenile idiopathic arthritis, there is not always correlation between 
disease severity and quality of life[203, 204] 
To assess whether the differences are due to treatment with HSCT it would be 
necessary to carry out a longitudinal study, evaluating quality of life in the same 
children over time, pre and post transplant. However, due to the rarity of this 
disease, and, because some patients are managed conservatively, and some 
curatively, it would take many years to gather a significant amount of data. The 
sample size for this study was small but still represents a large proportion of the 
children with CGD in the UK and Ireland. It would be difficult to undertake a 
larger study of quality of life in CGD without performing an international study. 
This would have limitations because of the need to complete questionnaires in 
different languages, having different normal values for different populations and 
different protocols for when to undertake HSCT. The only country that could 
perhaps undertake a study with a larger population would be the United States. 
6.2.2 Emotional and behavioural difficulties 
This study demonstrates that parents report children with CGD are at increased 
risk of emotional difficulties when compared to the normal population. This has 
been described previously in a cohort of children with CGD in the UK[6]. This 
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study did not include the same children as previously tested as they are now 
older than 16. This would suggest that it is likely to be a true finding as it has 
been replicated. Parents of the post-HSCT group did not demonstrate the same 
increased risk of emotional difficulties, instead, having scores similar to normal. 
Parents of non-HSCT children also reported a higher total score, presumably at 
least in part, due to the increased emotional score. This represents an overall 
increased risk of emotional and behavioural difficulties. The post-HSCT group 
had a significantly lower total score compared to the non-HSCT group showing 
that they are at less risk of emotional and behavioural difficulties. 
The post-HSCT group also had a significantly lower score for hyperactivity 
compared to the non-HSCT group. Although the non-HSCT group hyperactivity 
score was not significantly abnormal there was a trend towards significance 
(p=0.052), which when compared to the much lower score for the post-HSCT 
group resulted in a significant difference. The lack of significance for the non-
HSCT group compared to normal may be a reflection of the small sample size. 
Samples were compared to population norms for boys given the very high 
percentage of boys in the group so this is not a reflection of hyperactivity being 
more common in males than females. 
There were no significant differences from normal or when comparing non-
HSCT and post-HSCT groups for the child self report data. However, the 
numbers involved in this were very small and therefore it would be difficult to 
draw any conclusions.  
The SDQ is not designed to diagnose emotional difficulties, for example, anxiety 
or depression, but it is a useful screen to identify risk. It is important for 
clinicians to recognise that children with CGD may have increased risk of 
emotional and perhaps behavioural difficulties. It is not always easy to identify 
these problems in a routine clinic appointment but by raising awareness of 
these issues for both clinicians and families it may be easier to talk about in 
clinic. Early recognition will allow for formal diagnosis of any emotional 
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problems and then for interventions to be put in place which may improve the 
situation.  
6.2.3 Self-esteem  
There were no differences in global self-esteem for non-HSCT and post-HSCT 
children when compared with each other and compared to published norms. 
Non-HSCT children did have significantly lower scores compared to norms for 
athletic competence. Whereas, the post-HSCT group had normal scores for 
athletic competence. This suggests that those with CGD do feel their disease 
impacts on the athletic abilities, compared to their peers. Interestingly, both 
groups had higher scores for conduct compared to the norms and this was 
statistically significant for the post-HSCT group. This is difficult to explain. It may 
be that children with a chronic illness such as CGD have less ability to get 
involved in activities that they feel would be seen as bad behaviour. They may 
have less physical and emotional energy for such activities. 
These results are limited by the fact that only small numbers of children were 
eligible (needing to be 8 years old or over) and completed the questionnaire. 
The questionnaire is not “user friendly”, being 3 pages long and involving a 
complex style of questioning. A number of questionnaires had to be excluded 
due to incorrect completion. Despite explanation some children struggled with 
the concept of either/or questions and, rather than choosing one side of the 
questionnaire to answer they ticked both sides. There is also a lack of UK 
norms for comparison. The questionnaires were validated in American schools 
and a number of different sample results were generated for children of different 
ages. The only published data for comparison encountered the same difficulty 
so generated combined scores from these sample groups in the questionnaires 
manuals[273]. These are the results that were used as norms, however, they 
may not reflect current UK norms. In order to improve the quality of conclusions 
it would be important to have up to date UK data from a control group to 
compare to. Given these limitations, it is very hard to draw any useful 
conclusions about self-esteem in CGD and those transplanted for it. 
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6.2.4 Cognitive function  
This study demonstrates that children with CGD and those transplanted for it 
have normal IQ. This differs from the study by Pao et al which showed a higher 
than expected proportion of patients with significantly low IQ[5].  It also differs 
from the findings by Titman et al which showed lower than expected IQ in 
children treated with HSCT for a range of primary immunodeficiencies[4]. The 
differences from Pao et al can perhaps be explained because that group was 
selected because of recognised psychological difficulties. Whereas, the children 
tested in this study were taken from across the UK cohort. This makes the 
results of the current study more generalisable. The differences from Titman et 
al’s work may be due to the fact that that study included children with primary 
immunodeficiencies that also have neurological involvement. 
The number of children involved in this study is small, although not markedly 
different from the numbers in Pao et al. It does represent a reasonable 
proportion of the UK paediatric CGD population. Some families were reluctant 
to participate in IQ testing because of the extra time commitment when they 
were keen to get home after clinic appointments. Some families were also put 
off by the word “test”. It is difficult to tell if those who did not participate were 
different in any way that may have biased results. 
Given the normal results it is impossible to draw any conclusions about the 
impact of inflammation on IQ in CGD. It may be that prolonged exposure to 
inflammation is required to demonstrate any reduction in IQ. Most studies 
looking at inflammation and cognitive function are in adults rather than children. 
The question may be better addressed in adults with CGD. It may also be that 
the test used was too limited to pick up any subtle cognitive difficulties. The 
work in CGD mice has focussed very much on specific areas of memory[244, 
245] that the WASI is not designed to test in detail. It may be that a more 
detailed assessment would identify subtle differences. The trade off for this 
study was convenience over detailed assessment. Given that a number of 
families did not participate in the WASI due to the time involved it is likely even 
fewer would have stayed for a more detailed evaluation. 
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It is reassuring, for families, however, that a screening test has not identified 
any major difficulties that will impact on education. 
6.3 Areas for further research 
Over the years a number of CGD registries have been established. These are 
important to document clinical features of the disease in different populations. It 
will be important to analyse data for adult patients with CGD that was collected 
alongside the data in this study to evaluate morbidity and mortality and consider 
whether it has changed since the findings of the original UK and Ireland registry 
were published. Adult data are also necessary to make comparisons with the 
published results from other registries. The European Society for 
Immunodeficiencies (ESID) does provide an online database for a wide range of 
immunodeficiencies including CGD[284]. However, at the moment this is unable 
to record the wide variety of detail which is a key strength of the UK and Ireland 
Registry. Work has been undertaken to collect more detail and hopefully this will 
be available soon. This will then run as a continually updated registry and 
reduce the need for manual updates of the UK and Ireland registry.  
This study has provided no additional knowledge regarding residual NADPH 
oxidase activity and clinical outcome, which is an important area for further 
work. A small number of patients obviously do well into late adulthood, as seen 
from case reports. This is significant because, it may be that a subgroup of 
patients does not require HSCT. As more evidence points to the benefits of 
HSCT it will be important to identify whether this is an unnecessary risky 
procedure in a few select patients. It would be interesting to see if it is possible 
to predict clinical course from NADPH oxidase levels measured in childhood. 
This is only going to be possible while we are not routinely transplanting all 
children early. It may be that international collaboration is needed with countries 
that are not as rapid in their move to transplant. 
This study did not identify any cognitive difficulties on gross screening. 
However, it may be that subtle deficits could be identified on more detailed 
examination. Given that mouse models highlight issues with memory this would 
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be an area for further work, specifically using measures to evaluate memory 
rather than IQ. It would also be interesting to evaluate cognitive function in 
adults with CGD as it may be that older patients do suffer from more difficulties 
due to longer exposure to inflammation and the risk of more infections. If any 
cognitive difficulties are identified it would be useful to look at any correlation 
with levels of inflammatory markers. As IL1β has been implicated in cognitive 
decline it would be interesting to measure this in CGD patients and correlate it 
with cognitive function. It would be interesting to also look at this in the post-
HSCT group. Given that our understanding of inflammation in CGD remains 
incomplete we cannot be sure at this stage that we ameliorate all complications 
from this with HSCT. 
Further examination of emotional difficulties in a larger cohort of CGD patients 
would be important. This study was only able to identify significant differences in 
parent reports. The lack of significant difference in child self-reports may be due 
to the small numbers involved. It would be important to evaluate self-reported 
emotional and behavioural difficulties in a larger sample of children. Again, this 
would probably need international collaboration and may be complicated by 
different normal values for different populations.  
The SDQ is, like the WASI, a screening tool so it cannot provide detail about 
what type of emotional difficulties a patient is experiencing. Further evaluation 
would be useful in those identified to high scores on the SDQ to elucidate the 
type of difficulties experienced. This is important in order to put in place the 
correct form of support. 
As discussed above, a longitudinal study of quality of life in the same patients 
pre and post transplant would be really useful to examine whether the better 
post-HSCT quality of life really was a result of the procedure and to examine 
reasons for this. However, this would be difficult to carry out due to the rarity of 
CGD. If that is not possible, a study of quality of life in a larger sample of non-
HSCT and post-HSCT patients would be beneficial, however, complicated by 
international variation. 
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The questionnaires used in this study were validated for children. However, 
there are also adults living with CGD and some who have undergone HSCT for 
it (either as a child or an adult). It is important to evaluate emotional well being 
and quality of life in these patients as well. If children are at risk of emotional 
difficulties and poor quality of life, then it is quite possible adults are as well. It 
would be important to recognise this, again, in order to provide appropriate 
support.  
Another area that this study has not addressed is the cost of treatment. There is 
significant interest in cost effectiveness of treatment options within the health 
service. CGD is likely to be an expensive condition to manage, for example, 
long courses of intravenous antifungal treatment have significant costs in terms 
of drugs and nursing time to administer them (in hospital or at home). Prolonged 
hospital admissions or frequent hospital visits also potentially result in time off 
work for parents.  Although HSCT is thought of as an expensive procedure, it 
may be that by providing a cure and reducing the need for admission or surgery 
after HSCT it is less expensive in the long term. Further detailed information 
about length of hospital admissions and medication given, along with time off 
work for parents would be needed to estimate life-time cost of managing CGD 
before comparisons could be made with HSCT. 
There are wider implications for the findings of this study, in terms of other 
primary immunodeficiencies and other non-malignant conditions treated with 
HSCT. As HSCT survival is improving it is, perhaps, time to evaluate the 
emotional wellbeing and quality of life of these children, particularly in those 
where best treatment remains open to debate. It is not true the HSCT results in 
improved quality of life in all conditions. In those treated for leukaemia, the post-
HSCT group had worse quality of life than the non-transplanted group[285]. 
Presumably, this is because they had more intensive treatment, with more 
complications and side effects. Providing further information in these areas is 
important for families when considering their options. Although a demonstration 
of better quality of life, for example, does not necessarily mean we should be 
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recommending HSCT for all it may help provide more information for families to 
consider when faced with incredibly difficult decisions. 
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Chapter 7 Conclusions 
These studies set out to evaluate the clinical outcome, cognitive function, 
emotional wellbeing and quality of life for children with CGD, treated 
conservatively or curatively. It hypothesised that children with CGD would have 
more morbidity when compared to those who have undergone HSCT. This has 
been confirmed.  It has shown that children who have undergone transplant for 
CGD have fewer infections and admissions to hospital than children that are 
managed conservatively. Post-HSCT survival is good 90%. Post-HSCT children 
also have better height for age compared to non-transplanted children and 
demonstrate improved height for age following HSCT.  
These studies have also shown that children with CGD are at increased risk of 
emotional and possibly behavioural problems when compared to healthy norms.  
These differences are not present in the post-HSCT group. There was little 
difference in self-esteem between the two groups. There was marked difference 
in perceived quality of life between non-transplanted and post-transplant 
children. This supports the hypothesis set out in chapter two. What was not 
expected was the post-transplant group rating their quality of life as similar to 
healthy norms. In contrast to the stated hypothesis and previously published 
work, children with CGD and those transplanted for it have normal IQ. 
These studies suggest children that have undergone HSCT for CGD fare better 
clinically and emotionally. This information is important for clinicians and 
families that care for children with CGD and also has wider implications for 
other children with primary immunodeficiencies. Although this does not provide 
an answer to the question “should we transplant all patients with CGD” it 
contributes important information to the on-going debate.
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Appendix 1: Details of data collected 
Patient details 
Name 
Address 
Date of birth 
Place of birth(if known) 
Gender 
Twin 
Diagnostic tests performed to establish/confirm diagnosis  
NBT 
Flow cytometric assay  
Other 
None of the above 
Date CGD diagnosis established: 
Genetic type of CGD 
X-linked 
Autosomal recessive    p22/p47/p67 defect 
Not known 
Method used to establish genetic subtype 
Molecular genetic analysis of mutation 
Family history  
Mothers/fathers/brothers/sisters/maternal uncle/other affected family members. 
 
Tested: normal/affected/not tested 
 If affected  carrier/CGD/alive/CGD dead 
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Also space for additional information/comments on pedigree 
Respiratory Complications 
Pneumonia   Date/organism/treatment/duration of admission 
Empyema   Date/organism/treatment/duration of admission 
Lung abscess   Date/organism/treatment/duration of admission 
Lung function tests  Date/Pefr/fev1/fvc/tlc/rv/ratio of fec/fec/saturation/diffus 
cap 
High resolution CT scan Date/Report (free field) key words,  
Bronchiectasis  Date of diagnosis/lobe/Type 
Gastrointestinal complications 
Colitis    Date/symptoms/treatment/complications 
Oesopahgeal stricture Date/symptoms/treatment/complications 
Pyloric outlet obstruction Date/symptoms/treatment/complications 
Appendicitis   Date/symptoms/treatment/complications 
Pancreatitis   Date/symptoms/treatment/complications 
Investigations   Date/findings-normal/abnormal and location of 
abnormality  
To include: 
 Ultrasound, Barium swallow, Barium meal follow through, Barium enema, White 
cell scan  
Endoscopy/colonoscopy Date/normal/abnormal/granulomas 
Assessment of nutrition  
Birth weight 
Weight  
Height  
BMI - (Body mass index) 
Original Initial Diagnosis  Oral facial granulomatosis/Crohn’s/other 
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Liver complications 
Hepatitis  Date/investigations/treatment/complications 
Liver abscess  Date/investigations/treatment/complications 
Surgery   Date/operation/complication/duration of admission 
 
Other major illnesses related to CGD –  
Documenting the date/location/organism/treatment/duration of hospital admission for: 
Suppurative adenitis 
Osteomyelitis 
Septic arthritis 
Sepsis 
Brain abscess 
Meningitis 
Subcutaneous abscess 
Urinary outflow obstruction/glomerulonephritis 
Renal infection/abscess 
Pericarditis 
Chorioretinal disease 
Other 
Other diseases     
Cancer    date of diagnosis/type 
Arthritis    
Discoid lupus erythematous     
Systemic lupus erythematous   
Other autoimmune disease  Type/Autoantibodies present 
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Prophylaxis 
Document current/previous prophylactic agents antibiotic/antifungal 
Other specific treatment steroids/granulocyte infusions/gamma 
interferon/TPN/other drugs 
Bone marrow transplant/gene therapy  
Date/conditioning/complications/duration of admission 
Post transplant medication 
Current patient status 
Alive/dead/unknown 
If dead  date of death/age at death/cause of death 
Date of last contact with patient 
Other specialists involved 
Other regional centres involved 
